MÉTODO DE MONTAGEM DE UM DISPOSITIVO MÉDICO
The autoinjector's mechanical plunger switch and touch sensor, along with a translation mechanism, address the issue of accidental activation, ensuring controlled drug delivery and enhanced user safety.
Patent Information
- Application Number
- BR112025025067
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-26
- Filing Date
- 2024-05-16
- Publication Date
- 2026-11-10
AI Technical Summary
Existing autoinjectors can be inadvertently activated when dropped or vibrated, and lack adequate control logic to stop injections appropriately, leading to premature drug implantation and user discomfort.
The autoinjector design includes a mechanical plunger switch with a polarizing member and a touch sensor to prevent accidental activation, combined with a translation mechanism and fluid path assembly to ensure controlled drug delivery.
Reduces the probability of inadvertent activation and enhances user safety by providing controlled drug administration with improved operation and comfort.
Abstract
Description
1 / 80 “ASSEMBLY METHOD OF A MEDICAL DEVICE” CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority over U.S. Provisional Patent Application Nos. 63 / 502,889, filed May 17, 2023; 63 / 508,709, filed June 16, 2023; and 63 / 570,138, filed March 26, 2024, which are incorporated herein by reference in their entirety. FIELD OF TECHNIQUE
[0002] This disclosure is directed to an autoinjector and related methods of use. INTRODUCTION
[0003] In many available autoinjectors, after activation by a user, a needle is implanted and fluid is delivered from the needle to the user. After fluid delivery is complete, the needle can be retracted for user comfort, needle safety, and positive product perception. However, many autoinjectors can be inadvertently activated when dropped or vibrated. Furthermore, many autoinjectors may lack adequate control logic to stop an injection when appropriate. SUMMARY OF THE DISCLOSURE
[0004] The present description describes, in general terms, a method of assembling a medical device. The method may comprise forming a first assembly including: a main body; a needle mechanism; and a sterile connector operationally connected to a portion of the needle mechanism and configured to receive a cartridge; wherein the needle mechanism and the sterile connector form a fluid path assembly that couples to the main body. The method may further comprise forming a second assembly that includes: a base end and a translation mechanism, wherein the translation mechanism is configured to engage the cartridge. The method may also comprise combining the first assembly with the second assembly.
[0005] Another aspect of the present description provides that a method of assembling a medical device may comprise the formation of a first assembly. Petition 870260002664, dated 12 / 01 / 2026, page 7 / 135 2 / 80 including: a main body with a base, a chassis, a circuit board configured as a controller and a movable activation switch relative to the base; a needle mechanism with a support, a conveyor movably coupled to the support, an actuator movably coupled to the support, a polarizing member configured to apply a polarizing force against the conveyor and a fluid conduit coupled to the actuator; a sterile connector operationally connected to a portion of the fluid conduit and configured to receive a cartridge; wherein the needle mechanism and the sterile connector form a fluid path assembly coupled to the base of the main body.The method may further comprise the formation of a second assembly comprising: a base end, an actuator connected to the base end, and a ball screw assembly with a first screw, a second screw threaded into the first screw, and a third screw threaded into the second screw; wherein the ball screw assembly may be coupled to the actuator and form a translation mechanism, configured to engage the cartridge. The method may further comprise the combination of the first assembly with the second assembly.
[0006] Another aspect of the disclosure provides that a method of assembling a first assembly of a medical device may comprise: forming a needle mechanism having a carrier, a switching valve movably coupled to the carrier, an actuator movably coupled to the carrier, and a biasing member communicating with the switching valve and the actuator; and a fluid conduit coupled to the actuator; forming a sterile connector configured to receive a cartridge; coupling the needle mechanism to the sterile connector to form a fluid path assembly; coupling the fluid path assembly to a base of the first assembly; and coupling a printed circuit board assembly to the base of the first assembly. BRIEF DESCRIPTION OF THE FIGURES
[0007] The attached figures, which are incorporated into and form part of this descriptive report, illustrate various examples and, together with the description, serve to explain the principles of the examples and modalities disclosed. Petition 870260002664, dated 12 / 01 / 2026, page 8 / 135 3 / 80
[0008] Aspects of the disclosure may be implemented in connection with embodiments illustrated in the accompanying figures. These drawings show different aspects of the present disclosure and, where appropriate, reference numbers illustrating similar structures, components, materials and / or elements in different figures are similarly labeled. It is understood that various combinations of structures, components and / or elements, in addition to those specifically shown, are contemplated and fall within the scope of the present disclosure.
[0009] Furthermore, there are many embodiments described and illustrated in this document. This disclosure is not limited to any single aspect or embodiment, nor to any combinations and / or permutations of such aspects and / or embodiments. In addition, each of the aspects of this disclosure and / or embodiments thereof may be employed alone or in combination with one or more of the other aspects of this disclosure and / or embodiments thereof. For the sake of brevity, certain permutations and combinations are not discussed and / or illustrated separately in this document. Notably, an embodiment or implementation described in this document as exemplary should not be interpreted as preferential or advantageous, for example, in relation to other embodiments or implementations; rather, it is intended to reflect or indicate that the embodiments are exemplary.
[0010] FIG. 1 is a perspective view of an autoinjector, according to an example from the disclosure.
[0011] FIG. 1A is a perspective view of a portion of an autoinjector housing according to the disclosure.
[0012] FIG. 1B is a perspective view of a portion of an autoinjector housing according to the disclosure.
[0013] FIG. 2 is a bottom view of an autoinjector according to the disclosure.
[0014] FIG. 3 is a side view of an autoinjector, showing an activation switch extending away from a tissue-facing surface, of Petition 870260002664, dated 12 / 01 / 2026, p. 9 / 135 4 / 80 according to the disclosure.
[0015] FIG. 3A is a cross-sectional view of an autoinjector, showing an activation switch extending away from a tissue-facing surface, according to the disclosure.
[0016] FIG. 3B is a cross-sectional view of an autoinjector, showing an activation switch in a partially pressed position, according to the disclosure.
[0017] FIG. 3C is a cross-sectional view of an autoinjector, showing an activation switch in a fully pressed position, according to the disclosure.
[0018] FIG. 4 is an exploded view of an autoinjector, according to the disclosure.
[0019] FIG. 4A is a schematic illustration of an autoinjector control system according to the disclosure.
[0020] FIG. 4B is an exploded view of an autoinjector according to the disclosure.
[0021] FIG. 4C is a perspective view of a portion of a housing and an electronic board, according to an aspect of the disclosure.
[0022] FIG. 5 is an exploded view of a needle mechanism according to the disclosure.
[0023] FIG. 5A is a perspective view of a fluid conduit according to the disclosure.
[0024] FIG. 5B is a cross-sectional view of a fluid conduit needle according to the disclosure.
[0025] FIG. 6 is a perspective view of the needle mechanism of FIG. 5 in a first position according to the disclosure.
[0026] FIGS. 7-11 are side views of the needle mechanism of FIG. 5.
[0027] FIG. 12 is a side cross-sectional view of a portion of an autoinjector according to the disclosure.
[0028] FIG. 13 is a side cross-sectional view of a mechanism of Petition 870260002664, dated 12 / 01 / 2026, page 10 / 135 5 / 80 drilling according to the disclosure.
[0029] FIG. 13B is a side cross-sectional view of an autosampler according to the disclosure.
[0030] FIG. 14 is a side cross-sectional view of a drilling mechanism according to the disclosure.
[0031] FIG. 15 is a side view of a needle insertion switch according to the disclosure.
[0032] FIG. 16A is a perspective view of a latch for an autoinjector according to an aspect of the disclosure.
[0033] FIG. 16B is a bottom view of an autoinjector and a latch according to the disclosure.
[0034] FIG. 16C is a cross-sectional view of an autosampler and a latch according to the disclosure.
[0035] FIG. 16D is a cross-sectional view of an autosampler and a latch according to the disclosure.
[0036] FIG. 16E is a perspective view of a latch for an autoinjector according to an aspect of the disclosure.
[0037] FIG. 16F is a side view of a latch for an autoinjector according to an aspect of the disclosure.
[0038] FIG. 17 is a bottom view of an electronic board for an autoinjector according to the disclosure.
[0039] FIG. 17A is a perspective view of an electronic board for an autoinjector according to the disclosure.
[0040] FIGS. 18-20 represent flowcharts of exemplary methods according to the disclosure.
[0041] FIGS. 20A and 20B represent graphs relating to electrical controls for an autoinjector according to the disclosure.
[0042] FIGS. 21-23 represent flowcharts of exemplary methods according to the disclosure.
[0043] FIG. 24 illustrates an exploded view of an autoinjector, according to the Petition 870260002664, dated 12 / 01 / 2026, p. 11 / 135 6 / 80 disclosure.
[0044] FIGS. 25A, 25B and 25C illustrate parts of an autoinjector fluid path assembly according to the disclosure.
[0045] FIGS. 26A and 26B illustrate an assembly of the main body of the autoinjector according to the disclosure.
[0046] FIG. 27 illustrates the fluid path assembly and the main body assemblies as per the disclosure.
[0047] FIGS. 28A and 28B illustrate the translation mechanism according to the disclosure.
[0048] FIG. 29A is a side view of a first screw of a lead screw assembly according to the disclosure.
[0049] FIG. 29B is a bottom perspective view of a first screw in a set of lead screws according to the disclosure.
[0050] FIG. 29C is a top perspective view of a first screw in a set of lead screws according to the disclosure.
[0051] FIG. 29D is a cross-sectional view along line AA of the first bolt of a lead bolt assembly shown in FIG. 29A according to the disclosure.
[0052] FIG. 30 illustrates a perspective view of the autoinjector as per the disclosure.
[0053] FIG. 31 illustrates a perspective view of the autoinjector as per the disclosure.
[0054] FIG. 32 illustrates a flowchart for assembling the autoinjector according to the disclosure.
[0055] FIG. 33 illustrates the use of object recognition during an exemplary assembly process of the autoinjector according to the disclosure.
[0056] FIG. 34 illustrates the use of object recognition during an exemplary assembly process of the autoinjector according to the disclosure.
[0057] FIG. 35 illustrates a temporary spring retainer used during an exemplary assembly process of the autoinjector according to the disclosure. Petition 870260002664, dated 12 / 01 / 2026, p. 12 / 135 7 / 80
[0058] Again, there are many modalities described and illustrated in this document. This disclosure is not limited to any single aspect or modality, nor to any combinations and / or permutations of such aspects and / or modalities. Each of the aspects of this disclosure and / or modalities thereof may be employed alone or in combination with one or more of the other aspects of this disclosure and / or modalities thereof. For the sake of brevity, many of these combinations and permutations are not discussed separately in this document.
[0059] Notably, for simplicity and clarity of illustration, certain aspects of the figures represent the overall structure and / or manner of construction of the various embodiments. Descriptions and details of well-known features and techniques may be omitted to avoid unnecessarily obscuring other features. The elements in the figures are not necessarily drawn to scale; the dimensions of some features may be exaggerated relative to other elements to enhance understanding of the example embodiments. For example, one skilled in the art will appreciate that cross-sectional views are not drawn to scale and should not be seen as representing proportional relationships between different components. Cross-sectional views are provided to help illustrate the various components of the represented assembly and to show their positioning relative to one another. DETAILED DESCRIPTION
[0060] Reference will now be made in detail to examples from this disclosure, which are illustrated in the accompanying figures. Wherever possible, the same reference numbers will be used throughout the figures to refer to the same or similar parts. In the discussion that follows, relative terms such as about, substantially, approximately, etc. are used to indicate a possible variation of ±10% in a stated numerical value.
[0061] As described above, existing autoinjectors may be inadvertently triggered when dropped or vibrated. Furthermore, existing autoinjectors may lack adequate control logic to interrupt an injection. Petition 870260002664, dated 12 / 01 / 2026, page 13 / 135 8 / 80 when appropriate. These shortcomings can lead to premature drug implantation, increase the complexity of drug self-administration, introduce user errors, and cause user discomfort. Consequently, this disclosure is directed to various embodiments of an injection device (e.g., autoinjector) for self-administration of drugs or other therapeutic agents by a user. Specifically, according to certain embodiments, a probability of inadvertent activation of the autoinjector can be reduced, and the autoinjector can incorporate further control logic that improves the operation of the autoinjector and the user experience.
[0062] Additional details of autoinjectors according to this disclosure can be found in PCT / US2018 / 031077 by Arnott, et al., filed May 4, 2018 and published as WO 2018 / 204779 A1, and in U.S. Application No. 18 / 055,895 by Grygus, filed November 16, 2022, the entirety of which is incorporated herein by reference. Additional details of vial piercing systems according to this disclosure can be found in U.S. Patent No. 10,182,969, filed March 10, 2016, the entirety of which is incorporated herein by reference. GENERAL SYSTEM
[0063] An example of such an autoinjector 2 is shown in FIGS. 1, 2 and 3. As shown in FIG. 1, the autoinjector 2 may include a housing 3 with a tissue engagement surface (e.g., bottom) 4 through which a needle can be implanted and retracted. As shown in FIGS. 1 and 1A, the housing 3 may include a transparent window 50. The transparent window 50 may allow a viewer to view one or more displays or view the interior of the autoinjector 2 and components therein, such as a primary container and / or a pharmaceutical product stored in the primary container.
[0064] In some embodiments, and as shown in FIG. 1, the autoinjector 2 may include a plurality of openings 51 configured to facilitate the displacement of sound generated within the housing 3 (for example, by a loudspeaker). The autoinjector 2 may have any dimensions suitable to allow the Petition 870260002664, dated 12 / 01 / 2026, p. 14 / 135 9 / 80 portability and self-connection by a user. In one example, the autoinjector 2 might have a length of about 2.98 inches, a width of about 2.07 inches, and a height of about 1.07 inches. However, other suitable values could also be used, including, for example, a length of about 0.5 inches to about 5.0 inches, a width of about 0.5 inches to about 3.0 inches, and a height of 0.5 inches to about 2.0 inches.
[0065] The autoinjector 2 can be oriented around a longitudinal axis 40 (e.g., an X-axis), a lateral axis 42 (e.g., a Y-axis) that is substantially perpendicular to the longitudinal axis 40, and a vertical axis 44 (e.g., a Z-axis) that is substantially perpendicular to the longitudinal axis 40 and the lateral axis 42.
[0066] As shown in FIG. 1, an adhesive patch 12 can be attached to the fabric attachment surface 4 to help secure the autoinjector 2 to a user's body (e.g., skin). The adhesive patch 12 can be formed from fabric or any other suitable material and may include an adhesive. The adhesive can be an aqueous or solvent-based adhesive or, for example, a hot-melt adhesive. Suitable adhesives also include acrylic-based, dextrin-based, and urethane-based adhesives, as well as natural and synthetic elastomers. In some examples, the adhesive provided in the patch 12 can be activated by contact with a user's skin. In yet another example, the patch 12 can include a non-woven polyester substrate and an acrylic or silicone adhesive. The patch 12 can be attached to the housing 3 by, for example, a double-sided adhesive or by other mechanisms such as ultrasonic welding.The plaster 12 may have a length dimension greater than the width of the autoinjector 2.
[0067] As shown in FIG. 2, the autoinjector 2 may include an opening 6, through which the needle can be implanted and retracted. An activation switch 1409 may be disposed on the tissue engagement surface 4 and may be configured to activate the autoinjector 2 or otherwise place the autoinjector 2 in a mode Petition 870260002664, dated 12 / 01 / 2026, page 15 / 135 10 / 80 ready. A touch sensor 1410 can also be disposed on the tissue engagement surface 4 and can be configured to assist an autoinjector 2 controller in determining whether the autoinjector 2 is placed on a user's skin (indicating that the autoinjector should fire or otherwise implant a needle), or whether the activation switch 1409 has been improperly activated (indicating that the operation of the autoinjector 2 should be interrupted). A connection port 13 can also be disposed on the tissue engagement surface 4 to facilitate programming of the autoinjector 2.
[0068] The autoinjector 2 can be configured to operate in three or more operating phases including, for example, an injection sequence activation phase, an injection phase and a retraction phase, each of which will be described in more detail in this document. The injection sequence activation phase, the injection phase and the retraction phase may be collectively referred to in this document as an injection sequence.
[0069] Referring to FIGS. 3A, 3B and 3C which show cross-sections of an autoinjector 2, the activation switch 1409 may be a mechanical plunger type switch. For example, the activation switch 1409 may include a plunger 1450 with a plunger contact surface 1452. The plunger contact surface 1452 may generally be circular in shape (or have another suitable shape) and may be large enough to be comfortably pressed by soft skin. In some embodiments, the plunger contact surface 1452 may have a diameter or width ranging from about 2 mm to about 10 mm, a diameter ranging from about 4 mm to about 8 mm, or a diameter of about 6 mm. The activation switch 1409 may further include a shaft 1442, a polarizing member 1444, a polarizing collar 1446 and a plunger flange 1454. The polarizing member 1444 may be a spring, for example, and may encircle the shaft 1442.The polarizing member 1444 can be fixed, or otherwise prevented from moving, at one end by the polarizing collar 1446. The plunger flange 1454 can be configured to contact or otherwise press a plunger switch 1448. For clarity, the term... Petition 870260002664, dated 12 / 01 / 2026, page 16 / 135 11 / 80 activation switch and / or reference to activation switch 1409, as used in this document, shall be understood as encompassing any or all components of activation switch 1409, including shaft 1442, polarizing member 1444, polarizing collar 1446, plunger switch 1448, plunger 1450, plunger contact surface 1452 and plunger flange 1454.
[0070] In a free state, that is, when the plunger 1450 is not pressed against a user's skin or otherwise, the plunger 1450 may extend outward from the tissue engagement surface 4, as shown in FIG. 3A. In the free state, the contact surface of the plunger 1452 may be at a distance from the tissue engagement surface 4 ranging from about 1 mm to about 16 mm, ranging from about 5 mm to about 12 mm, or at a distance of about 8.5 mm. In the free state, the polarizing member 1444 can propel the plunger 1450 to extend out of the fabric engagement surface by pressing against the polarizing collar 1446. In the free state, the plunger flange 1454 may be in contact with, or otherwise press, the plunger switch 1448. When the plunger flange 1454 is in contact with, or otherwise presses, the plunger switch 1448, an electrical circuit associated with the plunger switch 1448 may be complete or closed.
[0071] When plunger 1450 is pressed against a user's skin or otherwise, plunger 1450 may initially move to a partially pressed state, as shown in FIG. 3B. In the partially pressed state, the polarizing member 1444 may be compressed against the polarizing collar 1446. The plunger flange 1454 may still be out of contact with, or otherwise not pressing, the plunger switch 1448. When the plunger flange 1454 is spaced, not in contact with, or otherwise not pressing the plunger switch 1448, the electrical circuit associated with the plunger switch 1448 may be broken or open. By this configuration, the autoinjector 2 may be maintained in a reduced power state while plunger 1450 is pressed, such as when the autoinjector 2 is in the packaging.
[0072] As shown in FIG. 3B, piston 1450 may not Petition 870260002664, dated 12 / 01 / 2026, page 17 / 135 12 / 80 must necessarily move to the fully pressed state (shown in FIG. 3C) before the piston flange 1454 is out of contact with the piston switch 1448. As shown in FIG. 3C, on the other hand, in the fully pressed state, the piston 1450 can be pressed inward so that the contact surface of the piston 1452 is flush or nearly flush with the fabric engagement surface 4.
[0073] The piston flange 1454 may be out of contact with the piston switch 1448, for example, after less than 5 mm of displacement by the piston 1450, after less than 3 mm of displacement by the piston 1450, after less than 1 mm of displacement by the piston 1450 or after about 0.75 mm of displacement by the piston 1450 — all when, for example, the maximum depression distance is 8.5 mm. In other words, the piston 1450 can transition from the free state, in which the piston flange 1454 is in contact with the piston switch 1448, to the partially pressed state, in which the piston flange 1454 is out of contact with the piston switch 1448, after moving only a portion of the maximum depression distance of the piston 1450 relative to the housing 3 of the autoinjector 2. For example, the piston 1450 can transition to the pressed state after moving only about 5%, about 10%, or about 20% of the maximum depression distance.Consequently, the autoinjector 2 and plunger switch 1448 may be sufficiently responsive when pressing the plunger 1450 against a user's skin. For example, the autoinjector 2 and plunger switch 1448 may be sufficiently responsive when pressed against skin of varying firmness or users with varying body fat percentages. Although examples of displacement distances for the plunger 1450 are provided in this document, it should be understood that this disclosure is not limited to any particular examples and any suitable displacement distance may be used.
[0074] The polarizing member 1444 may be sufficiently rigid so that, in the free state, the piston flange 1454 remains in contact with, or otherwise continuously presses, the piston switch 1448. The member of Petition 870260002664, dated 12 / 01 / 2026, page 18 / 135 13 / 80 polarization 1444 can also be of a rigidity so that plunger 1450 can be comfortably pressed against a user's skin. The polarization member 1444 can be polarized to keep plunger 1450 in the free state.
[0075] Although the activation switch 1409 is shown in FIGS. 3A-3C as a mechanical plunger type switch, it should be understood that the activation switch 1409 may be any other suitable type of switch, such as a rocker switch, directional switch, toggle switch, temperature switch and the like. Furthermore, although the electrical circuit associated with the plunger switch 1448 is described in this document as closed when the plunger 1450 is in the free state and open when the plunger 1450 is in the pressed state, it should be understood that an opposite configuration may be used. For example, the electrical circuit associated with the plunger switch 1448 may be open when the plunger 1450 is in the free state and closed when the plunger 1450 is in the pressed state.
[0076] A method of controlling the autoinjector 2 according to the positions of the activation key 1409 will be described below in more detail with reference to FIG. 23.
[0077] Furthermore, as shown in FIG. 4B, in some embodiments, the autoinjector 2 may include a plurality of LEDs 52. The LEDs 52 may be arranged in a ring-like formation or any other suitable formation. As described in more detail below, the light of one or more LEDs 52 may be indicative of various operating states of the autoinjector 2. AUTOINJECTOR HOUSING
[0078] Referring to FIGS. 1A and 1B, the housing 3 of the autoinjector 2 may include an upper portion 30. The upper portion 30 may form a portion of the housing 3 opposite the tissue engagement surface 4. The upper portion 30 may include a transparent window 50 through which a user may be able to see the contents of the autoinjector 2, including a vial and / or a drug contained in the vial. The transparent window 50 may be positioned on one side of the upper portion 30 and Petition 870260002664, dated 12 / 01 / 2026, p. 19 / 135 14 / 80 can be shaped so that it conforms to a rounded / curved contour of the upper portion 30, as shown in FIG. 1. The transparent window 50 can generally be rectangular in shape with rounded corners.
[0079] The upper portion 30 may also include a plurality of transparent windows 54. The transparent windows 54 may be formed on an upper surface of the upper portion 30 and may be arranged in any suitable configuration, such as a circular configuration, an oval configuration, a rectangular configuration, or a linear configuration, for example. The transparent windows 54 may be spaced circumferentially from each other, for example. The transparent windows 54 may allow the light from one or more LEDs located within the housing 3 to be visible to a user. The light from one or more LEDs may be indicative of various operating states of the autoinjector 2, as described in this document.
[0080] The transparent window 50 and the transparent windows 54 can be integrally formed as part of the upper portion 30. As shown in FIG. 1B, the upper portion 30 can include a transparent portion 500 formed from a transparent material. The transparent portion 500 can be contiguous, so that the transparent window 50 and the transparent windows 54 are formed from a single piece of transparent material. Furthermore, the transparent portion 500 can be integrated into the upper portion 30 so that the upper portion 30, including the transparent window 50 and the transparent windows 54, is manufactured as a single piece.
[0081] To form the upper portion 30 as a single piece, the upper portion 30 can be manufactured using a double-discharge molding process, for example. FIG. 19 illustrates an exemplary method 1900 of molding the upper portion 30 using double-discharge molding or insert molding. In step 1910, a first material can be deposited in a first mold with a first core and a first mold cavity. The first material can have low opacity and can be, therefore Petition 870260002664, dated 12 / 01 / 2026, page 20 / 135 15 / 80 example, a transparent material for the transparent window 50 and the transparent windows 54. The first material could be, for example, transparent acrylic, clarified acrylonitrile butadiene styrene (ABS), polycarbonate, polyvinyl chloride (PVC) or polyethylene terephthalate glycol (PETG). The first mold could be configured, for example, to form a transparent portion 500.
[0082] In step 1920, the first core and the material in the first mold cavity can be moved within a second mold cavity to form a second mold. When moved, the first core can retain the first material. The second mold can be configured, for example, to form the upper portion 30. In step 1930, a second material can be deposited in the second mold cavity in which the first material is contained. The second material can be deposited around the first material and the first core in the unoccupied space of the second mold cavity to form the upper portion 30. The second material can be a material with high opacity, such as white plastic. The second material can be, for example, ABS, polycarbonate, ABS-polycarbonate blend, PVC, or PETG.
[0083] Consequently, the generally opaque upper portion 30, which includes the transparent window 50 and the transparent windows 54, can be formed from two different materials to form a single piece. Forming the upper portion 30 as a single piece can reduce the total number of steps required to assemble the autoinjector 2. For example, in some embodiments, no steps or fastening materials or adhesives are required to join transparent and opaque portions of the housing. Avoiding unnecessary assembly steps can further improve the appearance of the cosmetic surfaces of the autoinjector 2. In addition, forming the upper portion 30 as a single piece can improve the overall structural integrity of the autoinjector 2. Furthermore, forming the upper portion 30 as a single piece can reduce or eliminate indentations in cosmetic surfaces. NEEDLE MECHANISM
[0084] Referring to FIGS. 5-11, a needle mechanism 20 includes a conveyor 202 that is movable (e.g., sliding) within the housing 3 Petition 870260002664, dated 12 / 01 / 2026, page 21 / 135 16 / 80 between a first position (FIG. 6) and a second position (FIG. 7). The needle mechanism 20 may also include a fluid conduit 300 that is mounted on the conveyor 202 and that can be deployed into a user and retracted by an actuator 320. An alternating valve 340 (e.g., an alternating valve actuator) may be configured to move the actuator 320 through an deployment gear 360 and a retraction gear 362. The alternating valve 340 may be coupled to a resilient member (e.g., a spring 370). A cover 380 (FIG. 5) may be coupled to the conveyor 202 to enclose various components of the needle mechanism 20.
[0085] Referring to FIG. 5, the fluid conduit 300 may extend from a first end 302 to a second end 304. As shown in more detail in FIG. 5A, the first end 302 may include a needle 306 which is configured to be injected into a user. The needle 306 may include a sharp and / or beveled tip and may generally extend along or parallel to the axis 44. The second end 304 may include a needle 308 which is substantially similar to the needle 306, but may be positioned within the autoinjector 2 to penetrate a cartridge 1302 (shown in FIG. 13 and described in more detail below) to access drugs to be injected into the user. The fluid conduit 300 may include an intermediate section 310 including a portion extending along or parallel to axis 40 and a second portion extending along or parallel to axis 40.The first and second portions of the intermediate section 310 can be joined into a serpentine section 312 that facilitates bending of the fluid conduit 300 and movement of the needle 306 along axis 44 during implantation in the user and during retraction out of the user. While a serpentine section 312 is shown, any other suitable shape, e.g., a coil, curve, or other shape that allows bending of the fluid conduit 300 is also contemplated. The serpentine section 312, or similar structure, can act as a cantilever when the needle 306 is implanted and / or retracted. The serpentine section 312 can also deflect the fluid conduit 300 to the implanted configuration shown in FIG. 5. Once the needle 308 penetrates and... Petition 870260002664, dated 12 / 01 / 2026, page 22 / 135 17 / 80 establishes fluid communication with cartridge 1302 (see, for example, FIG. 14), drugs can move from cartridge 1302, through needle 308, intermediate section 310 and needle 306 (pierced through the user's skin) and to the user. In some examples, the fluid conduit 300 may include only metal or a metal alloy. In other examples, the fluid conduit 300 may be any other suitable material, such as, for example, polymers or similar. Needle 308 and intermediate portion 310 may define a 22 or 23 gauge thin-walled needle, while needle 306 may be a 27 gauge thin-walled needle. Other needle sizes ranging from, for example, 6 gauge to 34 gauge and other needle wall thicknesses, such as regular wall, extra-thin wall and ultra-thin wall may also be used as appropriate.The Fluid Conduit 300 can reduce the amount of material that comes into contact with drugs, reduce joints and assembly steps, and require less sterilization than conventional devices.
[0086] As shown in FIG. 5B, the needle 308 can be configured to include a needle tip 308a and a side port 308b. The side port 308b can be fluidly connected to the fluid path 308c and allow fluid to enter the fluid conduit 300 through one side of the needle 308, as opposed to the needle tip 308. A rear wall of the side port 308b can be inclined at an angle θ relative to a longitudinal axis of the fluid path 308c. In some embodiments, the angle θ can be between about 20° and 60°, between about 30° and 50°, or about 40°. By configuring the needle 308 in this way, the needle 308 can be optimized to pierce the primary container of the autoinjector 2, which can be a sealed cartridge or a vial.The relative positioning of the needle tip 308a and the side port 308b can allow the primary container seal to be punctured without piercing or otherwise cutting a portion of the seal with an opening for the fluid path 308c. In this way, the entry of punctured or cut particles from the seal into the fluid path 308c can be minimized or avoided.
[0087] Needle 306 can be configured substantially similarly to needle 308, as shown in FIG. 5B. Alternatively, in Petition 870260002664, dated 12 / 01 / 2026, page 23 / 135 In some embodiments, one or both needles 306 and 308 may be a 3-bevel needle, a 5-bevel needle, or any other suitable type of needle. In some embodiments, one or both needles 306 and 308 may be a pencil-point needle with a round hole or any other hole of suitable shape.
[0088] The conveyor 202 may be formed of plastic (e.g., injection-molded plastic), a metal, metal alloy or similar and may include a flange 204 with an opening 206 and posts 210 and 212. The conveyor 202 may also include an opening 216 through which a needle or other fluid conduit may be implanted. The opening 216 may be a slot recessed from an end surface of the conveyor 202 or, in an alternative embodiment, the entire perimeter of opening 216 may be defined by the conveyor material 202. The conveyor 202 also includes a drive path 218. The drive path 218 may be a slot in the conveyor 202 extending along or parallel to the shaft 44. The drive path 218 may be configured to receive a drive protrusion 320, such as, for example, protrusion 330 discussed in more detail below.The conveyor 202 may also include an alternator valve path 220, along which the alternator valve 340 may move, as described in more detail below.
[0089] The conveyor 202 may also include a stop 240 which is configured to engage with the alternating valve 340. The stop 240 may be a cantilever with a fixed end 241 (FIG. 8) and a free end 242 (FIG. 8). The stop 240 may include an inclined ramp 243 (FIGS. 9 and 12) which, when engaged or pushed by a ramp 1500 (described with reference to FIG. 12), causes the stop 240 to deflect around the fixed end 241. In a first position, the free end 242 may block or otherwise impede the movement of the alternating valve 340 and, in a second configuration, may allow the movement of the alternating valve 340. The relationship between the stop 240 and the shuttle 340 will be discussed in more detail later in the application.
[0090] The actuator 320 includes two racks 322 and 324 (shown in FIG. Petition 870260002664, dated 12 / 01 / 2026, page 24 / 135 19 / 80 8) parallel to each other and arranged on opposite sides of the actuator 320. The racks 322 and 324 may include teeth and may be configured to engage and drive the rotation of the deployment gear 360 and the retraction gear 362, respectively. The actuator 320 may include a lumen 326 (or a strip, recess, or other suitable structure) (FIG. 5) which is configured to receive the needle 306 of the fluid conduit 300. The actuator 320 may also include the protrusion 330 (FIGS. 6 and 7) which is configured to slide within the drive path 218 of the conveyor 202. The protrusion 330 may include a hook-type configuration which may lock onto the impediment 600, as described in more detail below.
[0091] With continuous reference to FIG. 5, the alternating valve 340 may include a rack 342 configured to engage with gears 360 and 362. The alternating valve 340 may also include an end surface 344 and a recess 346 extending along a length of the alternating valve 340 in the same direction as the rack 342. A slot 348 (FIG. 9) may extend along the length of the recess 346. The slot 348 may extend through the middle of the recess 346 and may extend along a whole or substantial whole of the recess 346.
[0092] The alternating valve 340 can move along the track 220 from a first initial position (FIG. 8) to a second intermediate position (FIGS. 9 and 10), and from the second position to a third final position (shown between the second and third configurations in FIG. 11). As the alternating valve 340 moves along the track 220, the rack 342 can first engage the deployment gear 360 and then the retraction gear 362. At certain times, the rack 342 engages at most one deployment gear 360 and retraction gear 362 at any given time. In some examples, such as when the rack 342 is arranged longitudinally between the extension gear 360 and the retraction gear 362, the rack 342 is not engaged with either the extension gear 360 or the retraction gear 362. The alternating valve 340 can be configured to Petition 870260002664, dated 12 / 01 / 2026, page 25 / 135 20 / 80 moves only along one axis (e.g., axis 40) and only in one direction along that axis. The force required to move the alternator valve 340 along the track 220 can be provided by the expansion of spring 370. Spring 370 can be compressed from a resting state, and the expansion of spring 370 can move the alternator valve 340 along track 220 through the series of positions / configurations set out above. In various positions of the alternator valve 340, different features of the autoinjector 2 can directly or indirectly block the movement of the alternator valve 340. Alternatively, it is contemplated that spring 370 can be diverted to a compressed configuration. In this alternative embodiment, spring 370 can be expanded from a resting state and the compression of spring 370 can move the alternating valve 340 along track 220 through the series of positions / configurations set out above.
[0093] The first position of the alternating valve 340, shown in FIG. 8, may correspond to an unused, non-implanted and / or new state of the autoinjector 2. In this first position, the actuator 320 may be in a non-implanted state. The alternating valve 340 is held in the first position by the placement of an impediment 600 in the path of the actuator 320 (FIG. 6). The impediment 600, which may be a housing shelf 3, or other suitable locking device, may prevent the movement of the actuator 320 by engaging and / or retaining the protrusion 330. Therefore, as the actuator 320, the deployment gear 360 and the rack 342 are coupled to each other, the locking of the actuator 320 also prevents the movement of the alternating valve 340. The alternating valve 340 may move from the first position to the second position by moving the impediment 600 relative to the conveyor 202 (or vice versa). In one example, the conveyor 202 is moved (e.g., to the left in FIG.6) while impediment 600 remains stationary.
[0094] When the path of the actuator 320 is free of the impediment 600 (FIG. 7), the spring 370 can expand and move the alternating valve 340 along the range 220. This linear movement of the alternating valve 340 can rotate the deployment gear 360 counterclockwise (or clockwise in other examples). Petition 870260002664, dated 12 / 01 / 2026, page 26 / 135 21 / 80 via rack 342 and rotation of deployment gear 360 can move actuator 320 downward along shaft 44, via rack 322 of actuator 320. This downward movement of actuator 320 can cause needle 306 to pierce a user's skin. In some examples, actuator 320 can be configured to move, relative to conveyor 202, along only shaft 44.
[0095] The alternating valve 340 can be moved by the expansion of the spring 370 until its end surface 344 touches the free end 242 of the stop 240, so that the alternating valve 340 is held in the second position shown in FIGS. 9 and 10. At this point, the free end 242 can prevent further expansion of the spring 370 and further movement of the alternating valve 340 along the range 220. In this second position, the fluid conduit 300 can be deployed into a user and the fluid from the cartridge 1302 can be injected into the user by means of the needle 306. Furthermore, while the alternating valve 340 is in the second position, the rack 342 can be engaged with the deployment gear 360 to hold the needle 306 in the deployed configuration. The alternating valve 340 can move from the second position to the third position by bending the stop 240 around its fixed end 241.Further details of this bending are set forth below in relation to FIGS. 12-14. The bending of the stop 240 may allow the spring 370 to continue to expand, propelling the alternating valve 340 further along the range 220. In some instances, the stop 240 may be received by and / or within the recess 346 of the alternating valve 340 and the ramp 243 may slide within the slot 348 as the alternating valve 340 moves from the second to the third position.
[0096] The movement of the alternating valve 340 from the second position to the third position can correspond to the retraction of the user needle 306 into the housing 3. In particular, the rack 342 can engage and rotate the retraction gear 362 in the same direction (e.g., counterclockwise or clockwise) when the deployment gear 360 has been rotated. The rotation of the retraction gear 362 can propel the actuator 320 back to a Petition 870260002664, dated 12 / 01 / 2026, page 27 / 135 22 / 80 retracted position by means of rack 324. The alternating valve 340 can reach the third position, where the actuator 320 is fully retracted, when its end surface 344 engages with a wall of the conveyor 202, when the free end 242 of the stop 240 reaches an end of the recess 346 and / or when the spring 370 reaches a resting state.
[0097] In some embodiments, once the actuator 320 moves from the deployed state back to the retracted state, it may be prevented from moving out of the retracted state. As a result, the needle 306 will be prevented from being redeployed into the user. In this configuration, the autoinjector 2 may be a single-use device (e.g., discarded after the completion of an injection). In other embodiments, the autoinjector 2 may be reset and reused. Furthermore, the deployment gear 360 and the retraction gear 362 may be the only rotating gears disposed within the autoinjector 2, in some instances. STERILE PIERCING SYSTEM AND CONNECTOR
[0098] FIGS. 13 and 14 show features of a 1300 piercing system of the autoinjector 2. Further details of exemplary piercing systems can be found in U.S. Patent Application Publication No. 2016 / 0262984 A1 by Arnott et al., published September 15, 2016, the entirety of which is incorporated herein by reference. The 1300 piercing system includes a primary container, which may be a cartridge 1302 with a first end 1304 and a second end 1306. The primary container may alternatively be a chamber, syringe, vial, flexible bag, or any other suitable fluid-containing structure.
[0099] The cartridge 1302 may include an open cavity 1308 at the first end 1304 and extending towards the second end 1306. The second end 1306 may include a neck 1310 with a cap 1312 that engages the neck 1310 to close the second end 1306. A septum 1314 may be positioned between the cartridge 1302 and the cap 1312 to assist in closing the second end 1306 and allow the needle 308 (by Petition 870260002664, dated 12 / 01 / 2026, page 28 / 135 23 / 80 example, a stacked needle) is inserted into cartridge 1302. The cavity 1308 can be closed at the first end 1304 by a piston 1316.
[0100] The 1302 cartridge may have a capacity of 5 mL in some instances, although any other suitable volume (e.g., 1 mL to 50 mL, or 2 mL to 10 mL, or 3 mL to 6 mL, or 2 mL to 5 mL, or another suitable range) may also be used depending on the drug to be dispensed. In other instances, the 1302 cartridge may have a capacity greater than or equal to 1 mL, or greater than or equal to 2 mL, or greater than or equal to 3 mL, or greater than or equal to 4 mL, or greater than or equal to 5 mL, or greater than or equal to 10 mL, or greater than or equal to 15 mL. The 1302 cartridge may contain and preserve a drug for injection in a user and may help maintain the sterility of the drug. The 1302 cartridge may have a neck diameter of 13 mm, a length of 45 mm, and an internal diameter of 19.05 mm. These values are merely examples, and other suitable dimensions may be used as appropriate.In some examples, the 1302 cartridge can be formed using conventional materials and may be shorter than existing devices, which can help the autoinjector 2 remain economical and small. The 1302 cartridge may be a shortened 10 mL ISO cartridge.
[0101] The septum 1314 may include an uncoated bromobutyl material or other suitable material. The piston 1316 may include a fluoropolymer-coated bromobutyl material and may also include a conical nozzle 1316a to help reduce dead volume within the cartridge 1302. The piston 1316 may include one or more rubber materials, such as, for example, halobutyls (e.g., bromobutyl, chlorobutyl, fluorobutyl) and / or nitriles, among other materials.
[0102] The drilling system 1300 may also include a top 1354 positioned at the second end 1306. The top 1354 may include a base 1355 positioned over the septum 1314 and the cartridge opening 1302. The top 1354 may include a chamber 1356 extending from the base 1355 in a direction away from the piston 1316. The chamber 1356 defines a cavity 1357 and includes an opening 1358 communicating with the cavity 1357. In some embodiments, the top 1354 Petition 870260002664, dated 12 / 01 / 2026, page 29 / 135 24 / 80 can be integrated into septum 1314 (e.g., integral or one-piece construction). In alternative embodiments (not shown), top 1354 can be supplied or initially mounted on fluid conduit 300 and not installed directly on / with cartridge 1302 and / or integrated into septum 1314.
[0103] A portion of the fluid conduit 300, such as the needle 308, a tube or similar, may extend through the opening 1358 of the chamber 1356 and into the cavity 1357, but not through the base 1355 in the pre-activated state. The opening 1358 may be pre-formed or may be formed by the penetration of the needle 308 through the chamber 1356. The opening 1358 of the chamber 1356 may form a sterile sliding seal around the needle 308, so that pathogens or other contaminants are prevented from passing into the cavity 1357. The needle 308 may move relative to the top 1354 without interrupting the sterile seal between them. The cavity 1357 may be sterile or aseptic, so that the internal surfaces of the cavity 1357 and the needle 308 are sterile. In another embodiment, cavity 1357 can be sterilized after needle 308 is inserted through opening 1358 and into cavity 1357.In alternative embodiments, instead of the top 1354, a flexible convoluted bellows (e.g., rubber) or bladder member may form the cavity 1357 and allow translation of the cartridge 1302 relative to the needle 308 (or vice versa). The flexible member may also seal or form a cavity 1354 around the needle 308 after sterilization.
[0104] The piston 1316 can be coupled to a translation mechanism 1366 which is configured to translate the piston 1316 and the cartridge 1302 in a direction towards the second end 1306. The movement of the piston 1316 towards the second end 1306 causes the piston 1316 to act against the contents inside the cartridge 1302 (e.g., drugs, medicines), which ultimately transfers force against the second end 1306 of the cartridge 1302, causing the cartridge 1302 to move along the longitudinal axis 40. The translation mechanism 1366 may include a 12 mm motor with a five-stage gear reduction (360:1). The translation mechanism 1366 may have spring contacts that create an electrical connection with an associated printed circuit board. Petition 870260002664, dated 12 / 01 / 2026, page 30 / 135 25 / 80 (for example, first electronic board 1402). The motor can be configured to generate a torque of approximately 136 mN*m at 36 rpm. These motor design parameters are merely examples and any other suitable motor can also be used.
[0105] The translation mechanism 1366 may include a lead screw mechanism 1558 coupled to the piston 1316 that extends axially by relative rotation about the longitudinal axis 40. This telescopic lead screw may have an output of 100 N, a stroke of 20 mm, and a 7° / 45° buttress thread shape with a pitch of 0.75 mm. Materials for the lead screw mechanism 1558 may include acetal and polybutylene terephthalate. The lead screw mechanism may extend into the piston 1316 to reduce the dead space behind the piston 1316. While the piston 1316 is shown in FIGS. 13 and 14 with longitudinally spaced threads, in some examples, such threads may not be present. In another exemplary embodiment (not shown), the translation mechanism 1366 may include a manually engageable surface or member that is manually manipulated by a user to move the piston 1316.For example, the drilling system 1300 may include a cartridge or plunger coupled to the rear side of the piston 1316. In another exemplary embodiment (not shown), the translation mechanism 1366 may include a pneumatic or hydraulic drive member that is actuated or initiated by a user to move the piston 1316. The drive member may be in the form of an expansion bellows, an expansion bag, an expansion diaphragm, or a seal or sliding piston, for example. Direct pneumatic or hydraulic pressure may provide the force required to move the piston 1316.
[0106] The drilling system 1300 also includes a collar 1390 coupled or fixed to the second end 1306. The collar 1390 may include a plurality of circumferentially spaced fingers 1392 that engage and encircle the neck 1310. The collar 1390 may be fixed or otherwise coupled to the second end 1306. The collar 1390 may include a wall 1390a that extends through Petition 870260002664, dated 12 / 01 / 2026, p. 31 / 135 26 / 80 less partially around the neck 1310, the second end opening 1306, the cap 1312, the septum 1314 and / or the top 1354. The wall 1390a of the collar 1390 may be positioned radially or laterally outward from the neck 1310 and extend longitudinally past the neck 1310, the cap 1312 and the septum 1314.
[0107] In the pre-activated state of the drilling system 1300 shown in FIG. 13, an edge 1393 of the collar 1390 may engage a corresponding cam, latch or actuating portion 1394 that extends radially or laterally into an actuator retaining member 1395. The retaining member 1395 may be sliding relative to the collar 1390. The collar 1390 and the retaining member 1395 may be configured so that, in the pre-activated state or arrangement shown in FIG. 13, at least one portion of the cam or actuating portion 1394 of the retaining member 1395 is positioned directly behind a retaining portion 1399 of a sliding actuator 1398 within the retaining member 1395. A wall 1391 of the actuator 1398 may extend into and through an end cap portion 1396 of the retaining member 1395 and into an inner portion of the retaining member 1395, and the retaining portion 1399 of the actuator 1398 may extend radially outward from the wall 1391.In some embodiments, the wall 1391 of the actuator 1398 may be substantially cylindrical and the retaining portion 1399 of the actuator 1398 may be a flange extending around one end of the wall 1391.
[0108] In the pre-activated state of the drilling system 1300, an elastically deformed polarizing or resilient member 1397 may be positioned between the cap portion 1396 of the retaining member 1395 and the retaining portion 1399 of the actuator 1398. The polarizing member 1397 may exert a force against the actuator 1398 in the pre-activated state of the drilling system 1300 acting in the direction of the cartridge 1302. The polarizing member 1397 may be any member effective in applying the force in the pre-activated state and then releasing such force after activation, as discussed below with reference to FIG. 14. In some embodiments, the polarizing member 1397 may be a conical or flat spring. Petition 870260002664, dated 12 / 01 / 2026, page 32 / 135 27 / 80
[0109] The needle 308 of the fluid conduit 300 can be fixed or coupled to the actuator 1398 so that the fluid conduit 300 moves with the actuator 1398. In the pre-activated state of the piercing system 1300, the needle 308 can be positioned inside the sterile cavity 1357, but not through the base 1355 of the top 1354, septum 1314 and / or in the cavity 1308 of the cartridge 1302.
[0110] In some embodiments, instead of the cavity 1357, the needle 308 may be positioned within a plug when the piercing system 1300 is in the pre-activated state. The plug may be a solid plug that is devoid of any holes, cavities or openings and may be formed of a first rubber material. The first rubber material may be permeable to a sterilizing gas, such as, for example, ethylene oxide or vaporized hydrogen peroxide. The first rubber material may include one or more of isoprene, ethylene propylene diene monomer rubber (class M) (EPDM) and styrene-butadiene, among others. The permeability of the first rubber material to a sterilizing gas may allow the needle 308, when disposed within the plug, to be sterilized before use. The plug may be molded around the needle 308, so that the needle 308 is impaled in the plug.
[0111] To move the drilling system 1300 from the pre-activated state of FIG. 13, the translation mechanism 1366 can be activated to move the piston 1316 towards the second end 1306 and translate the cartridge 1302 along the longitudinal axis 40 towards the actuator 1398. Since the needle 308 is not yet in fluid communication with the cartridge 1302, the activation of the translation mechanism 1366 applies pressure against the fluid contained in the cartridge 1302, which is then applied to the cartridge 1302 itself. This pressure also causes the edge 1393 to push against and deflect the actuating portion 1394 radially outward. Without the actuating portion 1394 blocking its path, the retaining portion 1399 and the needle 308 are moved toward the cartridge 1302 by the expansion of the polarizing member 1397.Actuator 1398 can be coupled to flange 204 of conveyor 202, and thus, this movement of actuator 1398 towards cartridge 1302 can also move conveyor 202 in the same direction. This. Petition 870260002664, dated 12 / 01 / 2026, page 33 / 135 The 28 / 80 movement corresponds to the movement of the conveyor 202 in relation to the housing 3 in FIGS. 6 and 7, which allows the protrusion 330 to release the impediment 600 to inject the needle 306.
[0112] The movement of the needle 308 towards the second end 1306 of the cartridge 1302 also causes the needle 308 to pierce the base 1355 of the top 1354, septum 1314 and cavity 1308, in fluid communication with the contents of the cartridge. 1302. Since needle 308 is in fluid communication with the cartridge 1302, the additional movement of the piston 1316 towards the second end 1306 propels the fluid through needle 308 and a remainder of fluid conduit 300. In some embodiments, the piercing system 1300 can be configured so that, after activation, no more of the needle 308 than the portion that was already positioned within the sterile cavity 1357 extends into the cavity 1308. This can help prevent contamination of the contents of the cartridge 1302 with non-sterile portions of the needle 308.
[0113] The polarizing member 1397 can be configured to expand so that the fluid conduit 300 pierces the top 1354 and / or the septum 1314 at a high speed, such as at a speed of at least about 10 mm / s or at least about 40 mm / s. The relatively rapid piercing of the top 1354 and / or the septum 1314 by means of the polarizing member 1397 can help prevent leakage of the contents of the cavity 1308 which may be under pressure by means of the piston 1316.
[0114] After the drugs have been dispensed to the user via needle 306, needle 306 can be automatically withdrawn from the user. Referring to FIGS. 12-14, the translation mechanism 1366 can be operated in a reverse mode, so that the rotation of the advance screw is in an opposite direction compared to the insertion step. This counter-rotation can cause piston 316 to move back to the first end 1304 and also causes cartridge 1302 to move in an opposite direction along axis 40 (compared to during fluid dispensing and needle 306 insertion). The movement of cartridge 1302 in the opposite direction can cause ramp 1500 Petition 870260002664, dated 12 / 01 / 2026, page 34 / 135 29 / 80 in FIG. 12 (which is fixed to wall 1391) pushes against the ramp 243 of the stop 240. This can cause the stop 240 to deflect around its fixed end 241 in the direction of arrow 240a and allow the alternating valve 340 to move from its second position to its third position to retract the needle 306 as set out above. In this way, the removal and insertion of the needle in a patient can be performed with a single spring inside the device.
[0115] It is further contemplated that fluid conduit 300 may be the only fluid conduit of the autoinjector 2 configured to be in fluid communication with cartridge 1302. Thus, drugs from cartridge 1302 may be implanted only through fluid conduit 300 and into the user during normal operation of autoinjector 2. Additionally, needle 306 may be the only needle of autoinjector 2 configured to be implanted in a patient. In this way, a single piece of metal or plastic may be used to transport fluid from cartridge 1302 to a patient. LOCKING COMPONENT (DROP PIN)
[0116] Referring to FIGS. 16A-16D, the autoinjector 2 may include a locking component 1610. As shown in FIG. 16A, the locking component 1610 may include a lock (e.g., a protrusion) 1612 with a curved surface 1614 and may further include a cover portion 1616. The cover portion 1616 may be shaped to conform to the tissue engagement surface 4 of the autoinjector 2, as shown in FIG. 16D. The cover portion 1616 and the tissue engagement surface 4 may be concave to receive an anatomical portion 1600 of a user. The anatomical portion 1600 may be, for example, a thigh, hip, arm, back, or any other body area suitable for injection. The latch 1612 can be connected to the cover portion 1616. In some embodiments, the locking component 1610 can be formed as a single piece, so that the latch 1612 and the cover portion 1616 are integrally connected.The 1610 locking component can be formed from any suitable rigid or semi-rigid material. The 1610 locking component can, for example, be formed from acrylonitrile. Petition 870260002664, dated 12 / 01 / 2026, page 35 / 135 30 / 80 butadiene styrene (ABS) and may also have a frosted transparent appearance indicating that the 1610 locking component is disposable.
[0117] As shown in FIGS. 16B-16C, the locking component 1610 can be disposed on or adjacent to the fabric attachment surface 4 of the autoinjector 2, so that the lock 1612 can extend to the autoinjector 2. The locking component 1610 can also be disposed on or adjacent to a liner 12a that can initially cover the adhesive patch 12 before use of the autoinjector 2. The locking component 1610 can be positioned relative to the liner 12a so that, after removal of the liner 12a from the adhesive patch 12, the locking component 1610 can also be removed from the fabric attachment surface 4. The lock 1612 can extend to the autoinjector 2 through the locking opening 1630 formed on the fabric attachment surface 4.When the locking component 1610 is disposed on or adjacent to the fabric attachment surface 4, the cover portion 1616 can be fixed to the fabric attachment surface 4 by means of an adhesive disposed between the cover portion 1616 and the fabric attachment surface 4. The locking component 1610 can be disposed on or adjacent to the fabric attachment surface 4 so that it is selectively removable by a user.
[0118] Referring to FIGS. 16C-D, when the locking component 1610 is disposed on or adjacent to the fabric engagement surface 4, the latch 1612 may extend to the autoinjector 2 so as to prevent the movement of one or more internal mechanisms of the autoinjector 2. For example, when the locking component 1610 is disposed on or adjacent to the autoinjector 2, the latch 1612 may extend to the autoinjector 2 so that the latch 1612 engages with one or more internal components of the autoinjector 2, preventing these components from moving and / or being activated.
[0119] Referring to FIG. 16D, when the locking component 1610 is disposed on or adjacent to the fabric engagement surface 4, the lock 1612 can extend to the autosampler 2 so that it is disposed within the perforation system 1300. As described earlier in this document, the collar 1390 Petition 870260002664, dated 12 / 01 / 2026, p. 36 / 135 31 / 80 can be coupled or fixed to the second end 1306 of cartridge 1302. As also described earlier in this document, when the piercing system 1300 is moved from the pre-activated state, cartridge 1302 and consequently collar 1390 can translate in a direction parallel to a longitudinal axis of cartridge 1302 towards the retention portion 1399. When the latch 1612 extends to the autoinjector 2 and is adjacent to collar 1390, the latch 1612 can prevent cartridge 1302 from translating towards the retention portion 1399 or otherwise prevent cartridge 1302 and collar 1390 from applying a force against the actuation portion 1394. Thus, even if the motor were somehow activated while the latch 1612 is in its locking position, fluid communication between needle 308 and cartridge would be prevented. 1302 could not be established and needle 306 could not be implanted outside of housing 3.Furthermore, when in the locking position, the latch 1612 can prevent the cartridge 1302 from moving towards the needle 308, thus preventing the deflection of the actuating portion 1394 and, consequently, preventing the retaining portion 1399 and the needle 308 from moving towards the cartridge 1302. In the event that the autoinjector 2 falls or is subjected to vibrations, the latch 1612 can also prevent the piercing system 1300 from being moved from the pre-activated state and, consequently, can prevent the cartridge 1302 from being pierced by the needle 308.
[0120] When the locking component 1610 is disposed on or adjacent to the tissue engagement surface 4, the locking component 1610 may additionally serve as a spacer between a user's skin and the tissue engagement surface 4. For example, the locking component 1610 may have a thickness such that the touch sensor 1410, described in more detail below, is unable to detect the user's skin, thus preventing inadvertent activation of the autoinjector 2. The locking component 1610 may have a thickness, for example, of about 1 mm and about 5 mm, or about 3 mm.
[0121] Consequently, the locking component 1610 can act as an effective safety mechanism to prevent inadvertent activation of the Petition 870260002664, dated 12 / 01 / 2026, page 37 / 135 32 / 80 autoinjector 2. When the locking component 1610 is positioned on or adjacent to the tissue engagement surface 4, the lock 1612 can prevent various internal components of the autoinjector 2 from moving. In the event that the autoinjector 2 is dropped before use, for example, the locking component 1610 can prevent inadvertent puncture of the cartridge 1302 and / or inadvertent initiation of an injection sequence. The locking component 1610 can also prevent such movement and / or inadvertent initiation of an injection sequence if the autoinjector 2 is subjected to vibration during transport.
[0122] If a user wishes to use and / or is ready to use the autoinjector 2, the user can separate the locking component 1610 from the fabric engagement surface 4, thus removing the lock 1612 from the locking opening 1630. The user can, for example, peel the covering portion 1616 from the fabric engagement surface 4. Alternatively, the user can peel the coating 12a away from the adhesive plaster 12, thus removing the locking component 1610 from the fabric engagement surface 4. By separating the locking component 1610 from the fabric engagement surface 4, the curved surface 1614 can allow the lock 1612 to swing within the locking opening 1630, thus allowing the lock 1612 to be easily removed from the locking opening 1630. With the lock 1612 removed from the locking opening 1630, the Autoinjector 2 may be in a state where it is ready for use so that, for example, an injection sequence can be initiated.
[0123] FIGS. 16E and 16F represent the locking component 1610 according to some embodiments. As shown in FIGS. 16E and 16F, the locking component 1610 may have an increased width (relative to the representation of the locking component 1610 in FIGS. 16A-16C) to ensure that the locking component 1610 extends over the touch sensor 1410 when the locking component 1610 is disposed in the autoinjector 2. In addition, the locking component 1610 may have a ribbed structure and may include air gaps or recesses 1618 and hinges 1620. The air gaps 1618 may inhibit the conduction of a capacitive field between the user's skin and the Petition 870260002664, dated 12 / 01 / 2026, page 38 / 135 33 / 80 touch sensor 1410 when autoinjector 2 is placed near the user with locking component 1610 in place. Hinges 1620 may allow locking component 1610 to flex when locking component 1610 is peeled off autoinjector 2. In some embodiments, a different and / or separate removable cover from locking component 1610 may extend over touch sensor 1410 to inhibit inadvertent skin detection. ELECTRONIC COMPONENTS
[0124] FIG. 4A shows a control system 1400 of the autoinjector 2. The control system 1400 may include components located on a first electronic board 1402 and a second electronic board 1404 and may also include a power source 1406. The first electronic board 1402 may include a controller 1408, an activation switch 1409, a touch sensor 1410, a needle insertion switch 1412 and an emitter 1414. The second electronic board 1404 may include a detector 1416, an audio module 1418, a visual module 1420 and a haptic module 1422. Although FIG. 4A represents the audio module 1418, the visual module 1420 and the haptic module 1422, as included on the second electronic board 1404; in some embodiments, one or more of the above modules may be included on the first electronic board 1402.One or more of the components of the first electronic board 1402 and the second electronic board 1404 may be operatively coupled to the controller 1408 and powered by the power source 1406. The controller 1408 may also be operatively coupled to the translation mechanism 1366 and may be configured to control the operation of the translation mechanism 1366 to initiate and control needle insertion and retraction as set forth above. The translation mechanism 1366 may be coupled to the first electronic board 1402 by means of one or more spring contacts during a final assembly step in which the cartridge 1302 is inserted into housing 3. As described earlier in this document, the translation mechanism 1366 may include a motor 1552, gear 1556, and a lead screw mechanism 1558.
[0125] Most of the autoinjector assembly 2 can occur, for example, in Petition 870260002664, dated 12 / 01 / 2026, page 39 / 135 34 / 80 an assembly line in a manufacturing facility. Then, two halves (or portions) of the device can be sent to a drug filling or final assembly facility. In fact, the two separate portions 1490 and 1492 do not need to be the same size, as illustrated in FIG. 4B. Once a drug vial, for example, cartridge 1302, is filled with a drug or other medication, cartridge 1302 can be assembled with a remainder of the autoinjector 2. For example, the two halves of the device (portions 1490 and 1492) can be assembled together with the filled drug cartridge 1302 in them. In one example, portion 1490 and translation mechanism 1366 can be fitted into place behind cartridge 1302. Portion 1490 can be part of housing 3 including a base or module configured to contain translation mechanism 1366 and its associated electronic components.Portion 1492 may be a part of housing 3 containing substantially all the other components described in this document, including, for example, the needle mechanism, the sterile connector, and the piercing mechanisms described in this document. In this example, an electrical connection of the translation mechanism motor 1366 must be made during the fitting of the translation mechanism 1366 behind the cartridge 1302 (i.e., during the assembly step where portions 1490 and 1492 and the cartridge 1302 are combined to form a complete and functional autoinjector 2). To accommodate such an electrical connection, the drive train of the translation mechanism 1366 may include one or more spring contacts 1494 (referring to FIG. 4C) that will contact the pads 1495 (also referring to FIG. 4C) on the first electronic board 1402 after assembly. Although not shown in FIG.4C, the drive train of the 1366 translation mechanism may include additional spring contacts that can contact additional pads on the first electronic board 1402 after assembly. Such additional spring contacts and additional pads may serve to connect additional components of the 1366 translation mechanism, such as a tachometer, a motor encoder, or any other sensors or devices, to the first electronic board 1402. Thus, the connection of the 1366 translation mechanism to the first electronic board 1402. Petition 870260002664, dated 12 / 01 / 2026, page 40 / 135 35 / 80 (including the 1408 controller) can be made without loose wires or other similar structures.
[0126] This assembly process can be relatively simpler than simpler devices (e.g., autoinjectors) with relatively more complex final assembly processes. As a result, the contemplated assembly process described in this document can lead to a reduction in labor costs. Additional details regarding the assembly of devices according to the present description are shown and presented below with reference to FIGS. 24-30.
[0127] In some embodiments, the autoinjector 2 may include a single (i.e., only or exactly one) electronic board 1710, as shown in FIGS. 17 and 17A, on which the control system components 1400 described earlier in this document may be positioned. As shown in FIG. 17A, the electronic board 1710 may include a first board segment 1712 and a second board segment 1714. The first board segment 1712 and the second board segment 1714 may be physically and electrically connected by means of a flexible segment 1716. The flexible segment 1716 may be, for example, a ribbon cable, a flexible conductive substrate, or the like. In some embodiments, the flexible segment 1716 may be formed of fiberglass board that is machined finely enough to flex and is sometimes referred to as semi-flexible. In some embodiments, the flexible 1716 segment may be formed from a flexible polymer.Flexible polymer can be formed by a process sometimes referred to as rigid-flexible, in which a sandwich of a first portion of fiberglass, flexible polymer, and a second portion of fiberglass is first formed. The first and second portions of fiberglass can subsequently be removed to leave the thin flexible polymer portion.
[0128] Electronic board 1710 may include one or more supports 1720 for mounting or otherwise securing electronic board 1710 to an interior of the autoinjector 2. The first board segment 1712 may further include a cutout 1718. The cutout 1718 may be positioned so that the first board segment 1712 can Petition 870260002664, dated 12 / 01 / 2026, page 41 / 135 Position 36 / 80 to allow the needle to pass through the 1718 cutout when implanted.
[0129] In some embodiments, the first segment of board 1712 may correspond to the first electronic board 1402 and the second segment of board 1714 may similarly correspond to the second electronic board 1404, each as described previously in this document. By connecting the first segment of board 1712 and the second segment of board 1714 by means of the flexible segment 1716, the first segment of board 1712 may be positioned adjacent to the fabric engagement surface 4 of the autoinjector 2, while the second segment of board 1714 may be positioned on an opposite side of the autoinjector 2 towards the upper portion 30 of the housing 3. Consequently, the single electronic board 1710 may be used to connect components located towards the fabric engagement surface 4 and to connect components located towards the upper portion 30.This configuration can facilitate the assembly of the autoinjector 2, eliminating the need for complex wiring or soldering.
[0130] As shown in FIG. 17, the electronic board 1710 can be positioned inside the housing 3. The first board segment 1712 can be positioned adjacent to the fabric engagement surface 4, while the second board segment 1714 can be positioned on an opposite side of the autoinjector 2 (e.g., behind the first board segment 1712 in FIG. 17). The flexible segment 1716 can be flexed or bent to maintain a connection between the first board segment 1712 and the second board segment 1714 in such positions.
[0131] The touch sensor 1410 may be incorporated into or on the first plate segment 1712 of the electronic board 1710. To allow proper detection of a user's skin, the touch sensor 1410 and the first plate segment 1712 may be located near the tissue engagement surface 4 of the housing 3. The tissue engagement surface 4 of the housing 3, or a portion thereof adjacent to the touch sensor 1410, may be sufficiently thin so that an electric field of detectable magnitude can form between the sensor and Petition 870260002664, dated 12 / 01 / 2026, page 42 / 135 37 / 80 touch 1410 and a user's skin. In some embodiments, the portion of the tissue engagement surface 4 adjacent to the touch sensor 1410 may be smaller than about 2 mm, about 1 mm, or less than about 1 mm. Furthermore, the portion of the tissue engagement surface 4 adjacent to the touch sensor 1410 may be made of a solid material, such as plastic. By forming the portion of the tissue engagement surface 4 adjacent to the touch sensor 1410 from a solid material, as opposed to a ribbed, perforated, or hollow material, a dielectric constant between the user's skin and the touch sensor 1410 can optimize the responsiveness of the touch sensor 1410.
[0132] Furthermore, the touch sensor 1410 can be positioned within or on the electronic board 1710 so as to be adjacent to or near the opening 6 through which the needle can be implanted. By positioning the touch sensor 1410 adjacent to or near the opening 6, the probability that the touch sensor 1410 can detect a user's skin when the autoinjector is properly positioned is increased. In addition, a curvature of the tissue engagement surface 4 can decrease the probability that the touch sensor 1410 can falsely interpret a flat surface, such as a table, as a user's skin, by creating a space between the touch sensor 1410 and the flat surface.
[0133] By incorporating the touch sensor 1410 within or on the electronic board 1710, the need for one or more wires and / or other circuitry connecting the touch sensor 1410 to a separate electronic board can be eliminated. The assembly of the autoinjector 2 can thus be simplified and the cost of the autoinjector can be reduced.
[0134] Since the electronic plate 1710 can be located adjacent to the tissue engagement surface 4, the electronic plate 1710 can include a cutout to allow the needle to be implanted through the electronic plate 1710 and subsequently through the opening 6. Furthermore, the electronic plate 1710 can be positioned so that the touch sensor 1410 is directly adjacent to the opening 6 and there is no gap between an edge of the touch sensor 1410 and the Petition 870260002664, dated 12 / 01 / 2026, page 43 / 135 38 / 80 opening 6. Alternatively, the electronic board 1710 can be positioned so that there is a gap between an edge of the touch sensor 1410 and the opening 6, and the gap has a maximum width of 5 mm, 2 mm or 1 mm, for example.
[0135] The controller 1408 can be configured to accept information from the system and system components described above and process the information according to various algorithms to produce control signals to control internal mechanisms of the autoinjector 2, including the translation mechanism 1366. Examples of such algorithms are described below with reference to FIGS. 18 and 2023. The processor can accept information from the system and system components, process the information according to various algorithms, and produce information signals that can be directed to the audio module 1418, visual module 1420, haptic module 1422, or other indicators of, for example, second electronic board 1404, in order to inform a user about the system status, component status, procedure status, or any other useful information being monitored by the system.The processor can be a digital IC processor, an analog processor, or any other suitable logic or control system that implements the control algorithms.
[0136] As discussed above in relation to FIGS. 3A and 3B, the activation switch 1409 may be a mechanical plunger-type switch extending away from the tissue engagement surface 4 of the autoinjector 2. The activation switch 1409 may include an electrical circuit that is complete unless the activation switch 1409 is pressed. For example, when the autoinjector 2 is attached to a user's skin, the switch 1409 may be pressed, breaking the electrical circuit and indicating to the controller 1408 that the autoinjector 2 should be activated. In order to conserve energy, the components of the autoinjector 2 may be in an inactive or sleep mode until the switch 1409 is activated. In yet another example, injector 2 may not receive power until switch 1409 is activated, and deactivating switch 1409 could completely cut off power to injector 2.While a mechanical plunger-type switch is disclosed, any other suitable mechanism for activating the autoinjector 2 may be used. Petition 870260002664, dated 12 / 01 / 2026, page 44 / 135 39 / 80 including, for example, a button pressed by the user, voice signals and a wireless signal from another electronic device, among others.
[0137] The touch sensor 1410 can be configured to help the controller 1408 determine whether the autoinjector 2 is properly implanted on a user's skin. In one example, the touch sensor 1410 can be a capacitive sensing electrode or any other device configured to differentiate contact with skin versus other materials, such as, for example, wood, plastic, metal, or other material. When the skin is in close proximity to the capacitive sensing electrode, a signal indicating such contact can be sent to the controller 1408. Thus, the touch sensor 1410 can serve to verify whether the autoinjector 2 is properly placed on a user's skin, even if the switch 1409 is pressed. The touch sensor 1410 can include a capacitive sensing electrode coupled to the first electronic board 1402 and also to an interior of the housing 3.Housing 3 and adhesive patch 12 can act as an overlay (insulator) that acts as a dielectric between the user's skin and the capacitive sensing electrode. Alternatively, the touch sensor 1410 can be incorporated within or on the electronic board 1710, as described previously in this document, so that the capacitive sensing electrode is also incorporated within or on the electronic board 1710. Contact of portions of housing 3 and / or adhesive patch 12 near the capacitive sensing electrode can cause the electrode capacitance to increase, for example, by about 1 to about 10 pF, indicating placement of the autoinjector 2 on a skin surface.
[0138] The needle insertion switch 1412 can be configured to send a signal to the controller 1408 that the needle 306 is implanted within a user. For example, referring to FIG. 15, the needle insertion switch 1412 may include a curved cantilever 1510 including a first contact 1512. The needle insertion switch 1412 may also include a second contact 1514. The first contact 1512 may be placed in electrical contact with the second contact 1514 when the needle 306 is implanted in the user. During the Petition 870260002664, dated 12 / 01 / 2026, page 45 / 135 40 / 80 needle 306 deployment, the actuator 320 can move downwards along axis 44 and deflect the curved cantilever 1510 and the first contact 1512 towards the second contact 1514. When the first contact 1512 and the second contact 1514 connect to each other, a signal can be sent to the controller 1408 indicating that the needle 306 has been successfully deployed in the user. The separation of the first contact 1512 and the second contact 1514 may indicate that the needle 306 has been retracted from the user.
[0139] The emitter 1414 and the detector 1416 can operate as an optical interruption sensor or photointerrupter in order to allow the controller 1408 to determine a state of the autoinjector 2. The emitter 1414 can be a light-emitting diode (LED) or other suitable light emitter and the detector 1416 can be, for example, a phototransistor configured to receive light emitted by the emitter 1414. In one example, the emitter 1414 can emit infrared light, although other suitable wavelengths of light can also be used. The use of infrared light can help reduce interference from external light.
[0140] As shown in FIG. 13B, the emitter 1414 and the detector 1416 can be arranged opposite each other within the housing 3 to allow a light beam 1430 to pass from the emitter 1414, through the cartridge 1302, to the detector 1416. The cartridge 1302 and any fluid contained therein can be at least partially transparent to the beam 1430, so that the beam 1430 can pass through the cartridge 1302 and its contents. As piston 1316 is moved toward the second end 1306 during drug delivery (referring to FIGS. 13 and 14), piston 1316, and in particular a protrusion of piston 1316, can interrupt beam 1430. When detector 1416 fails to detect beam 1430, a signal can be sent to controller 1408, which can interpret the signal to indicate an end of an injection (e.g., that all the drug contained in cartridge 1302 has been expelled).In some examples, the refraction path of beam 1430 can be considered by positioning emitter 1414 and detector 1416 relative to each other. For example, beam 1430 can be refracted as it passes through cartridge 1302 and any liquid contained therein, and emitter 1414 and the... Petition 870260002664, dated 12 / 01 / 2026, p. 46 / 135 41 / 80 detector 1416 can be offset from each other accordingly. Additionally, emitter 1414 and detector 1416 can be offset from a housing center 3 so that piston shoulder 1316 can block beam 1430. In at least some instances, an optical interruption sensor or similar mechanism can help prevent false positives in the event of a drive train failure. That is, the optical switch can help controller 1408 determine that an injection has not been completed more accurately than other mechanisms.
[0141] Audio module 1418 may include a speaker or similar device to provide audio feedback to the user. Openings in housing 3 may facilitate the displacement of sound from audio module 1418 to the user. Audio module 1418 may generate a tone or other sound at the beginning and end of the injection and / or to indicate any other reference point during the injection, such as an error, for example. Visual module 1420 may include one or more LEDs or similar devices to provide visual feedback to the user. Visual module 1420 may include different colored LEDs to provide various messages to the user. For example, a plurality of blue LEDs arranged in a ring may be used to display the progress of the injection over time, one or more green LEDs may be used to display the completion of the injection, and a red LED may be used to display an error to the user.Any other suitable colors, combinations, and / or numbers of LEDs may be used in various examples. For example, a combination of red, blue, and purple LEDs may be used. In one arrangement, eight LEDs may be arranged in a circle with a diameter of about 26.5 mm or a diameter of about 10.0 mm to about 40.0 mm. It should be understood that this illustrative quantity and positioning of LEDs is not intended to be limiting, and any quantity and / or positioning of LEDs may be used. The LEDs may be activated sequentially around the circle to indicate the progress of an injection (e.g., in a progress ring arranged in a clock-like manner – see, for example, LEDs 52 in FIG. 4B). The 1408 controller may also be configured to receive feedback from... Petition 870260002664, dated 12 / 01 / 2026, p. 47 / 135 42 / 80 multiple sensors and resizing a speed at which multiple LEDs are activated based on sensor feedback. For example, the LEDs in the progress ring may be activated in three or more operating phases including, for example, an injection sequence activation phase, an injection phase, and a retraction phase. Those skilled in the art will recognize that autoinjector 2 may have more or fewer than the three operating phases described above. There may be an expected time to complete each phase, but there may also be some variability in the actual times presented during any of the aforementioned operating phases of autoinjector 2. An algorithm can be used to help prevent premature activation of LEDs, for example, when a certain phase finishes earlier than expected, or to have progress along the ring stopped when a certain phase takes longer than expected.At any point, the algorithm can divide the estimated time remaining for the drug delivery to be completed by the number of unactivated LEDs in the progress ring, to determine a rate at which the remaining LEDs in the progress ring should be activated.
[0142] For example, before the activation phase of the injection sequence, the LEDs can be activated at a rate equal to the estimated time of the entire drug delivery process (e.g., the estimated time to complete the entire activation phase of the injection sequence, the injection phase, and the retraction phase) divided by the total number of non-activated LEDs in the progress ring. In other words, the estimated time of the entire drug delivery process can be divided by a number that is the total number of LEDs in the progress ring minus any LEDs already activated. Thus, if, for example, one LED is already activated, the estimated time of the entire drug delivery process can be divided by one less than the total number of LEDs in the progress ring.
[0143] After the activation phase of the injection sequence is complete, the LEDs can be activated at a rate equal to the sum of the estimated times to complete the remaining phases (e.g., the injection phase and the retraction phase) divided by the number of unlit LEDs in the progress ring. After the injection phase is complete, the LEDs can be activated at a rate equal to the estimated time to Petition 870260002664, dated 12 / 01 / 2026, page 48 / 135 43 / 80 completes the retraction phase, divided by the number of unlit LEDs.
[0144] In some embodiments, subsets of LEDs can be used to indicate the progress of the injection phases. For example, in embodiments with eight LEDs positioned in an autoinjector housing 2, a first LED can be illuminated to indicate needle insertion. The second to seventh LEDs can then be illuminated sequentially to indicate injection phase progress. Finally, the eighth LED can be illuminated to indicate needle retraction. Although an exemplary configuration of the LEDs and corresponding logic has been described, it should be understood that the number of LEDs for each phase of an injection process can be varied as desired.
[0145] The visual module 1420 may also include a display screen, touch screen or other suitable device to provide one-way or two-way communication with the user. The visual module 1420 may be visible to the user from outside housing 3 by means of a window in housing 3. The haptic module 1422 may include, for example, a haptic motor configured to generate vibrations that can be felt by the user. The vibrations may signal the start and end of an injection and / or may help to provide additional information to a user.
[0146] The 1408 controller can be coupled to a wireless communication module and an antenna. The wireless communication module can be configured to transmit data from the 1408 controller to, for example, a mobile device, computer, cell phone, or similar. The wireless communication module can be configured to transmit information via one or more wireless modes, such as, for example, Bluetooth, Bluetooth Low Energy (BLE), Near Field Communication (NFC), infrared, cellular networks, and wireless networks, among others. The antenna can be any suitable device configured to assist the wireless communication module in transmitting and / or amplifying data. Thus, the 1408 controller can be configured to transmit user and / or autoinjector 2 diagnostic information, information regarding the completion of an injection, and / or information regarding an autoinjector 2 error state to a Petition 870260002664, dated 12 / 01 / 2026, page 49 / 135 44 / 80 user device or to the cloud. Indicative signals for needle insertion and / or premature removal of the device can also be transmitted via the wireless communication module. The 1408 controller can also be configured to transmit temperature information to the autoinjector 2. For example, a user may be able to monitor, via a mobile device and / or application, for example, the temperature of autoinjector 2 when autoinjector 2 is removed from cooling. The 1408 controller can also receive activation and / or delay commands via the wireless communication module. The 1408 controller can also receive operating adjustment commands, such as commands related to adjusting the preferred operating speed, for example. In some modes, the 1408 controller can receive a command to pause an injection.
[0147] In some embodiments, the 1408 controller can communicate with a mobile application on a user's mobile device via the wireless communication module. The mobile application can be configured to facilitate the use of the autoinjector 2 and improve the user experience. In some embodiments, the mobile application can be used to automatically check the expiration date of a medication contained in the autoinjector 2. Such functionality can relieve a user from having to manually check the expiration date and can improve user safety. Based on an expiration date, the mobile device can be configured to alert the user and / or disable the use of the autoinjector 2. In some embodiments, the mobile application can be used to alert a user about product recall and / or can disable the device in the event of product recall.For example, the mobile application can access a database via the internet to determine if certain devices, many devices, medications, and / or many medications have been recovered. In some embodiments, the mobile application can be configured to confirm whether the autoinjector 2 and / or medication is authentic as opposed to counterfeit. The mobile application can do this, for example, by cross-referencing a product serial number or digital signature with a database of authenticated products. In some... Petition 870260002664, dated 12 / 01 / 2026, page 50 / 135 In modes 45 / 80, one or more portions of the autoinjector 2 can be disposable, and the mobile app can be configured to confirm the authenticity of such portion or portions before use.
[0148] In some embodiments, the mobile application can be used to facilitate an injection sequence. For example, the mobile application can synchronize with the events of an injection sequence and provide contemporaneous instructions to the user on which tasks (e.g., press switch 1409, hold autoinjector 2 against the skin, remove autoinjector) to perform at what times. In some embodiments, the instructions can be audibly narrated. In some embodiments, the instructions can be provided visually via a display on the mobile device. In some embodiments, the mobile application can be configured to provide detailed indication of the progress of an injection sequence. For example, the mobile application can provide text, visual, and / or audio progress indications with greater granularity than shown by LEDs, for example, as described earlier in this document.
[0149] In some modalities, the mobile application can be configured to record and store a date and / or time of an injection. Based on the date and / or time of the injection and a user's prescription information, the mobile application can be configured to automatically create a reminder for a subsequent injection. In some modalities, after the completion of an injection, the mobile application can be configured to provide a notification to the user with positive feedback for adherence to a prescription regimen. In some modalities, the mobile application can provide points and / or rewards for continued adherence.
[0150] In some embodiments, the mobile application can be configured to authenticate an autoinjector user before use. For example, the mobile application, in connection with the user's mobile device, can use biometric identification, two-factor authentication, or any other suitable authentication protocol to confirm the user's identity before an injection. After user authentication, the mobile application can cause the autoinjector to be activated or deactivated. Petition 870260002664, dated 12 / 01 / 2026, page 51 / 135 46 / 80 another way is to be unlocked. This user authentication can inhibit the misuse and / or waste of expensive medications by people who are not the intended user.
[0151] In some embodiments, the mobile application can be configured to detect operating conditions of the autoinjector 2. For example, the mobile application can be configured to detect the device's battery level and, in the case of a low battery indication, the mobile application can be configured to provide a notification to the user indicating a need to charge the device. In some embodiments, the mobile application can be configured to detect mechanical and / or electrical malfunctions of the autoinjector 2 and transmit this information to the user.
[0152] FIG. 18 shows an exemplary method 2000 according to the disclosure. The method 2000 can begin at step 2002, where a user can position the autoinjector 2 on their body so that the tissue engagement surface 4 comes into contact with a skin surface. The user can position the autoinjector 2 on their skin after removing the locking component 1610, as described earlier in this document, thus allowing the touch sensor 1410 to detect skin proximity. The autoinjector 2 can be mounted in any suitable location, such as, for example, the thigh, abdomen, shoulder, forearm, arm, leg, buttocks, or other suitable location. The autoinjector 2 can be fixed to the skin by the adhesive patch 12. Fixing the autoinjector 2 in step 2002 may cause the activation switch 1409, which extends outward from the tissue engagement surface 4, to be pressed and break a circuit.A circuit break may cause a signal to be sent to controller 1408 indicating that activation switch 1409 has been pressed. Alternatively, any other suitable mechanism may switch on or activate autoinjector 2 before or after step 2002. After pressing activation switch 1409, autoinjector 2 may emit an audio tone and / or illuminate one or more LEDs (e.g., one or more LEDs of a first color, e.g., blue) to indicate pressing activation switch 1409. Petition 870260002664, dated 12 / 01 / 2026, page 52 / 135 47 / 80
[0153] Once autoinjector 2 is activated in step 2002, method 2000 can proceed to step 2004, where controller 1408 can determine if tissue engagement surface 4 is positioned on a skin surface. In step 2004, controller 1408 can receive a measurement from touch sensor 1410 indicating whether autoinjector 2 is positioned on the skin or another surface. If controller 1408 determines that touch sensor 1410 is in contact with the skin, for example, when a capacitance value received from touch sensor 1410 is within a predetermined range, method 2000 can proceed to step 2008. If controller 1408 determines that the touch sensor is not in contact with the skin, for example, if the capacitance measurement received from touch sensor 1410 indicates that autoinjector 2 is in contact with a non-cutaneous surface such as wood or metal, method 2000 can proceed to step 2006.In step 2006, autoinjector 2 can be placed in an error condition. In the error condition, an LED may be activated (e.g., a red LED) to indicate to the user that an error has occurred, or a message may be displayed on a display screen. In some examples, autoinjector 2 may need to be manually reset before an injection can be completed. In other examples, autoinjector 2 may revert to step 2004, where controller 1408 continuously attempts to determine if touch sensor 1410 is in contact with the skin. Method 2000 may also require touch sensor 1410 to be in contact with the skin throughout the injection.Thus, if at any point during the injection, the controller 1408 determines that the touch sensor 1410 is no longer in contact with the skin, the controller 1408 may interrupt the injection (e.g., by interrupting further movement of the translation mechanism 1366), may generate an error signal or message, and may retract the needle 306 if it has been extended. By interrupting the injection and retracting the needle 306, a risk of dispensing the drug outside the body (i.e., a wet injection) and / or needle stick injuries may be mitigated. After the determination of step 2004, the autoinjector 2 may emit an audio tone and / or illuminate one or more LEDs to indicate that the autoinjector 2 is positioned on the skin surface. In one example, one or more LEDs. Petition 870260002664, dated 12 / 01 / 2026, page 53 / 135 An additional 48 / 80 of the first color may be illuminated at this stage to indicate further injection progress.
[0154] In step 2008, the controller 1408 can send a signal to activate the translation mechanism 1366. Once activated, the translation mechanism 1366 can move towards the second end 1306 of the cartridge 1302 (referring to FIGS. 13 and 14), causing the cartridge 1302 itself to move in the same direction. This can cause the needle 308 to move in the opposite direction to access the cartridge 1302 as established above. The movement of the actuator 1398 and the needle 308 causes the conveyor 202 to move in the same direction, which establishes the chain of events that ultimately deploys the needle 306 into the user by the mechanisms established in FIGS. 5-11. The translation mechanism 1366 will continue to move towards the second end 1306 until a desired quantity of the drug contained in the cartridge 1302 is dispensed to the user.After the translation mechanism is activated, autoinjector 2 can emit an audio tone and / or illuminate one or more LEDs to indicate that injection is in progress. For example, additional LEDs of the first color can be illuminated as injection progresses to provide the user with a visual indication of the progress.
[0155] Method 2000 can proceed to step 2010, where controller 1408 can determine if the injection is complete. This determination can be based on the interruption of beam 1430 by piston 1316 (as described with reference to FIGS. 4A, 13 and 14). That is, when beam 1430 is broken (not received by detector 1416), controller 1408 can determine that the injection is complete. Once controller 1408 determines that the injection is complete, controller 1408 can send a signal to the translation mechanism 1366 to reverse the direction of rotation of the lead screw, which can cause ramp 1500 to push against ramp 243 of stop 240, allowing needle 306 to retract as discussed above with reference to FIG. 11. In one example, controller 1408 may institute a delay after receiving an indication that beam 1430 has been interrupted. The delay may be, for example, 0.1 to 60 seconds. Petition 870260002664, dated 12 / 01 / 2026, p. 54 / 135 49 / 80
[0156] An additional end-detection mechanism may be used instead of or in combination with the interruption-type sensor described above. For example, a current from the translation mechanism motor 1366 may be used to determine whether an injection has been completed. That is, when the piston 1316 reaches the second end 1306 of the cartridge 1302, the current in the motor will increase (e.g., as a result of the piston 1316 engaging the end of the cartridge 1302), signaling the ejection of all or substantially all of the contents of the cartridge 1302. An exemplary combination may include the use of beam 1430, where interruption of beam 1430 indicates that, for example, 90 to 98 percent of the injection has been completed. Then, the current from the translation mechanism motor 1366 may be analyzed to determine whether the remaining 2 to 10 percent of the injection has been completed.In another example, instead of using an optical switch, a delay in the start of the translation mechanism 1366 can be used by the controller 1408 to determine when to reverse the translation mechanism 1366. In one example, this delay might be, for example, from about 1 to about 120 seconds, although other suitable times are also contemplated. In any case, the start delay can be long enough to allow for the emptying of cartridge 1302. In yet another example, beam 1430 can be used in combination with an encoder. The encoder can be configured to detect a piston position 1316. If the encoder were used to detect the piston position 1316 alone, a problem in the drive train could inhibit accurate detection. For example, piston 1316 might rotate when pushed by the lead screw. Such rotation could cause uncertainty as to the actual position of piston 1316.When used in conjunction with beam 1430, however, controller 1408 can be configured to recalibrate the encoder in response to an interruption of beam 1430. Such recalibration can allow controller 1408 to update the actual position of the encoder and resume accurate detection of piston 1316 position using the encoder.
[0157] After determining that the injection is complete, autoinjector 2 may emit an audio tone and / or illuminate one or more LEDs to indicate completion of the injection. Petition 870260002664, dated 12 / 01 / 2026, page 55 / 135 50 / 80 injection. In some examples, one or more LEDs of a second color (e.g., green) that is different from the first color may be illuminated to signal to the user that the injection is complete. In some examples, all the LEDs on the device may be illuminated with the second color, and other indications may also be used. For example, all LEDs may be illuminated with the second color and may flash intermittently at the end of the injection.
[0158] In some examples, the time of an injection procedure, measured from the initial activation of the activation switch 1409 to the user's needle retraction 306 after drug dispensing, may be from about 20 seconds to about 90 seconds, or from about 25 seconds to about 60 seconds, from about 30 seconds to about 45 seconds, or less than or equal to about 120 seconds, or less than or equal to about 90 seconds, or less than or equal to about 60 seconds, or less than or equal to about 45 seconds, or less than or equal to about 30 seconds. This time represents a significant improvement over existing devices, for which the time of an injection can be much longer and, in some cases, up to about 9 minutes or even more.
[0159] Method 2000 may also include additional steps. For example, method 2000 may include determining whether a drug within cartridge 1302 is too cold for dispensing to the user, whether the power source 1406 has sufficient power to complete an injection, whether the needle 306 has been deployed and / or retracted prematurely, whether the current of the translation mechanism motor 1366 is within an appropriate range, and whether an injection procedure has extended beyond an acceptable maximum procedure time. When the controller 1408 detects any of the above errors, it may communicate such errors to the user and may terminate an ongoing injection, for example, by interrupting or reversing the translation mechanism 1366 and retracting the needle 306 from the user. The autoinjector 2 may emit an audio tone and / or illuminate one or more LEDs indicating any of the above additional steps.For example, one or more LEDs of a third color (e.g., red) that is different from the first and second colors. Petition 870260002664, dated 12 / 01 / 2026, page 56 / 135 51 / 80 can be illuminated.
[0160] FIG. 20 shows an exemplary method 2020 of controlling a torque of the translation mechanism motor 1366 and detecting when the motor stops. In step 2022, the controller 1408 can initiate an injection sequence. As described earlier in this document, an injection sequence can be initiated by pressing the activation switch 1409 against a user's skin and / or detecting the user's skin by the touch sensor 1410. During the injection sequence, a voltage can be applied to the translation mechanism motor 1366 to activate the motor.
[0161] In step 2024, as the injection sequence progresses, controller 1408 can maintain the motor of the translation mechanism 1366 at a constant speed. The constant speed can be, for example, a rotational speed measured in revolutions per minute (RPM). Controller 1408 can maintain the motor at a constant speed by varying the voltage applied to the motor. For example, when a higher load is applied to the motor due to an obstruction, increased fluid pressure, increased component friction, or any other cause, controller 1408 can compensate for the increased load by increasing the voltage applied to the motor. Conversely, when a load applied to the motor is reduced, controller 1408 can compensate for the reduction in load by decreasing the voltage applied to the motor. Maintaining the motor at a constant speed can reduce the likelihood of the user experiencing pain at the injection site.For example, maintaining a constant motor speed can prevent the bolus from becoming excessively large, thus mitigating the risk of pain.
[0162] During the injection sequence, the 1408 controller can monitor the current supplied to the motor. The motor current can be indicative of the torque generated by the motor. For example, a higher motor current may indicate a higher torque being generated by the motor. In step 2026, the 1408 controller can determine if the motor current exceeds a first current limit. The first current limit can be determined and / or adjusted based on a maximum torque that can be safely generated by the motor. The maximum torque can be Petition 870260002664, dated 12 / 01 / 2026, page 57 / 135 52 / 80 achieved, for example, when the injection sequence is somehow obstructed. If controller 1408 determines that the motor current does not exceed the first current limit, method 2020 can revert to step 2024 and controller 1408 can continue to maintain the motor at constant speed. If, on the other hand, controller 1408 determines that the motor current exceeds the first current limit, method 2020 can proceed to step 2028.
[0163] In step 2028, the 1408 controller can reduce the motor voltage to keep the motor current below a second current limit. In some embodiments, the second current limit may be higher than the first current limit and may correlate more closely with the maximum torque that can be safely generated by the motor. In some embodiments, the second current limit may be less than or equal to the first current limit. In the event that the injection sequence is obstructed, the motor speed may decrease and the motor impedance may decrease. As the motor impedance decreases, a lower voltage may be required to keep the motor current below the second current limit. The 1408 controller can monitor an average motor voltage applied to the motor. The average motor voltage may be, for example, a time average.
[0164] Steps 2024 to 2028 of method 2020 can generally be illustrated by the graph shown in FIG. 20B, where a curve representing a relationship between the voltage applied to the motor of the translation mechanism 1366 and the current consumed by the motor is graphically represented. The curve can be characterized by the following equation: V = iR + Vemf
[0165] In the equation above, V is the voltage applied to the motor, i is a current consumed by the motor, R is a resistance of the motor coil, and Vemf is a back electromotive force acting against the applied voltage at a given speed. As shown in FIG. 20B, the curve may include a constant speed region, in which the motor can be maintained at a constant speed (step 2024). In the constant speed region, Vemf can remain Petition 870260002664, dated 12 / 01 / 2026, page 58 / 135 53 / 80 is approximately constant, and the curve may be approximately linear.
[0166] As shown in FIG. 20B, as a load (i.e., a torque) acting on the motor of the translation mechanism 1366 increases, the current consumed by the motor may increase. As the current approaches a Maximum Current, a voltage applied to the motor can be reduced, thus keeping the current below the Maximum Current (steps 2026 and 2028). The current consumed by the motor can be kept below the Maximum Current using integral proportional (PI) regulation. As shown, there may be a minimum voltage for the motor below which the motor may stop.
[0167] Steps 2030 to 2038 of method 2020 may correspond to a control sequence to prevent motor stalling. FIG. 20A represents a graph that may depict the voltage applied to the motor and the current consumed by the motor over time and according to steps 2030 to 2038.
[0168] In step 2030, controller 1408 can determine if the average motor voltage has decreased below a first limit voltage. The average motor voltage decreasing below the first limit voltage may indicate that the injection sequence is obstructed. If controller 1408 determines that the average motor voltage has not decreased below a first limit voltage, method 2020 can revert to step 2028, in which controller 1408 can continue to maintain the motor current below the second current limit. FIG. Figure 20A illustrates five intervals during which the 1408 controller can maintain the motor current at a constant value (e.g., below the second current limit): between approximately 35 seconds and approximately 37 seconds, between approximately 39 seconds and approximately 41.5 seconds, between approximately 43.5 seconds and approximately 46 seconds, between approximately 48 seconds and approximately 50.5 seconds, and between approximately 52.5 seconds and approximately 55 seconds.As shown in FIG. 20A, the voltage applied to the motor during each interval may decrease, albeit with some fluctuations, to keep the motor current below the second current limit. Although the voltage during each interval in FIG. 20A is shown as decreasing, the voltage does not necessarily need to decrease to keep the motor current below the limit. Petition 870260002664, dated 12 / 01 / 2026, page 59 / 135 54 / 80 second current limit, but instead it can remain flat in certain situations.
[0169] If, on the other hand, the 1408 controller determines that the average motor voltage has decreased below the first limit voltage, the 1408 controller may cause the injection sequence to be paused for a first time interval. By causing the injection sequence to be paused, the 1408 controller may stop applying voltage to the motor. In some embodiments, the first time interval may be 2 seconds, for example. FIG. 20A illustrates four such pauses: between approximately 37 seconds and approximately 39 seconds, between approximately 41.5 seconds and approximately 43.5 seconds, between approximately 46 seconds and approximately 48 seconds, and between approximately 50.5 seconds and approximately 52.5 seconds.
[0170] The first time interval may be long enough to allow the fluid pressure within the autoinjector 2 to dissipate. The first time interval may also be short enough so that the user is not required to remove the autoinjector 2 from the user's skin (e.g., the first time interval is set to be shorter than a typical user reaction time to falsely identify the end of the injection). The first time interval may also be indicated by the illumination of one or more of the progress ring LEDs or other light within the autoinjector 2 and visible to a user. The LEDs may be illuminated, for example, in a particular pattern or according to a particular color scheme to indicate the first time interval and that the injection sequence is paused rather than interrupted.
[0171] After pausing the injection sequence, controller 1408 can continue the injection sequence at step 2034. To continue the injection sequence, controller 1408 can resume supplying voltage to the translation mechanism motor 1366. At step 2036, controller 1408 can determine if the average motor voltage has decreased below the first limit voltage within a second time interval. The second time interval can be shorter than the first time interval and can be defined and / or determined as indicative of confirmation that the injection sequence is obstructed. The Petition 870260002664, dated 12 / 01 / 2026, page 60 / 135 The 55 / 80 second time interval could be, for example, about 0.9 seconds. If the motor voltage has not decreased below the first limit voltage within the second time interval, method 2020 can revert to step 2030. If, on the other hand, controller 1408 determines that the motor voltage has decreased below the first limit voltage within the second time interval, method 2020 can proceed to step 2038, at which point controller 1408 can cause the injection sequence to be aborted.
[0172] In some embodiments, the 1408 controller may execute step 2026 continuously as it executes steps 2028 through 2036. For example, the 1408 controller may continue to determine if the motor current exceeds the first current limit as steps 2028 through 2036 are performed. If the motor current continues to exceed the first current limit, method 2020 may proceed through steps 2028 through 2036 as described earlier in this document. In the event that the motor current falls below the first current limit, on the other hand, method 2020 may revert to step 2024 and the 1408 controller may maintain the motor at a constant speed.In other words, if a high load on the motor, due to obstruction, high fluid pressure, or similar, dissipates during the execution of steps 2028 to 2036, the 1408 controller can simply revert to maintain a constant motor speed instead of unnecessarily proceeding through any remaining steps.
[0173] Consequently, method 2020 can allow controller 1408 to effectively distinguish between situations where the needle may be partially blocked or a high frictional force may be acting against the injection sequence and situations where the injection sequence is insurmountably obstructed. In the former situations, autoinjector 2 may have the ability to complete the injection sequence and the injection sequence may not be terminated prematurely. In the latter situations, autoinjector 2 may not have the ability to complete the injection sequence and the injection sequence may be terminated appropriately. In such situations, autoinjector 2 may emit an audio tone and / or illuminate one or more LEDs to indicate that the injection was terminated before the Petition 870260002664, dated 12 / 01 / 2026, p. 61 / 135 56 / 80 conclusion. Method 2020 can also properly terminate an injection sequence in which piston 1316 extends completely, indicating that cartridge 1302 is empty. Method 2020 can also allow autoinjector 2 to be used in an emergency if, for example, a user performs an injection without first warming autoinjector 2 to decrease the viscosity of the medication. Method 2020 can also allow an injection of a viscous medication to proceed at a slower rate than the motor and gear reduction ratio might allow.
[0174] FIG. 21 shows an exemplary method 2100 of detecting the end of a drug dose using emitter 1414 and detector 1416. Method 2100 can be used, for example, to detect a moment when a complete dose of drug has been dispensed to a user and to terminate the corresponding injection sequence.
[0175] In step 2102, the controller 1408 can initiate an injection sequence. As described earlier in this document, an injection sequence can be initiated by pressing the activation switch 1409 against a user's skin and / or detecting the user's skin via the touch sensor 1410. In step 2104, the controller 1408 can periodically switch the emitter 1414 on and off. The emitter 1414 can be switched on and off rapidly in a square wave pattern, so that the emitter 1414 switches off and on several times per second. The cycling of the emitter 1414 on and off can allow the detector 1416 to be exposed to the light produced by the emitter 1414 in combination with ambient light and also to ambient light alone.
[0176] In step 2106, controller 1408 may receive a first signal from detector 1416 corresponding to a time when emitter 1414 is off. The first signal may correspond to and / or be indicative of ambient light detected by detector 1416. In step 2108, controller 1408 may receive a second signal from detector 1416 corresponding to a time when emitter 1414 is on. The second signal may correspond to and / or be indicative of light emitted by emitter 1414 in combination with ambient light, as detected by detector 1416. Petition 870260002664, dated 12 / 01 / 2026, page 62 / 135 57 / 80
[0177] In step 2110, controller 1408 can calculate a difference between a first light value represented by the first signal and a second light value represented by the second signal. The difference can be indicative of how much light detected by detector 1416 is attributable to light emitted by emitter 1414 as opposed to ambient light. In step 2112, controller 1408 can determine if the difference is less than a threshold value. If controller 1408 determines that the difference is not less than a threshold value, method 2100 can revert to step 2106. If, on the other hand, controller 1408 determines that the difference is less than the threshold value, controller 1408 can terminate the injection sequence in step 2114.
[0178] Consequently, method 2100 can be used to reduce the impact of ambient light when detecting the end of a drug dose. Specifically, method 2100 can address a situation where light from emitter 1414 is prevented from reaching detector 1416 indicating the end of a dose, but ambient light is able to reach detector 1416 and create a false negative reading indicating that the end of a dose has not been reached.
[0179] FIG. 22 shows another exemplary method 2200 of detecting the end of a drug dose using emitter 1414 and detector 1416. Method 2200 can be used, for example, to detect a moment when a complete dose of drug has been dispensed to a user and to terminate the corresponding injection sequence.
[0180] In step 2202, the controller 1408 can initiate an injection sequence. As described earlier in this document, an injection sequence can be initiated by pressing the activation switch 1409 against a user's skin and / or detecting the user's skin via the touch sensor 1410. In step 2204, the controller 1408 can activate the emitter 1414 or otherwise cause the emitter 1414 to emit light.
[0181] In step 2206, controller 1408 can cause the injection sequence to continue for an initial time period. The initial time period can be a predetermined time period corresponding to a duration in Petition 870260002664, dated 12 / 01 / 2026, page 63 / 135 58 / 80 which a full dose cannot be, or is unlikely to be, dispensed. For example, the first time period may be between about 20% and 50% of the total injection time. During the first time period, controller 1408 is unable to interrupt the injection sequence in response to a signal received from detector 1416 (but may still interrupt the injection sequence due to obstructions or stagnation, as discussed with reference to FIG. 20).
[0182] In step 2208, after the end of the first time period, controller 1408 can determine if an amount of light received by detector 1416 is less than a first threshold light value. Controller 1408 can make the determination based on a signal received from detector 1416 indicating light received by detector 1416. The first threshold light value may correspond to an amount of light received by detector 1416 at the end of a dose. If controller 1408 determines that the amount of light received by detector 1416 is not less than the first threshold light value, controller 1408 can continue the injection sequence and method 2200 can remain in step 2208. If, on the other hand, controller 1408 determines that the amount of light received by detector 1416 is less than the first threshold light value, the method can proceed to step 2210.
[0183] In step 2210, controller 1408 can determine if the amount of light received by detector 1416 is greater than or equal to the first threshold light value. If controller 1408 determines that the amount of light received by detector 1416 has risen to or above the first threshold light value, controller 1408 can continue the injection sequence and method 2200 can revert to step 2208. If, on the other hand, controller 1408 determines that the amount of light received by detector 1416 has remained less than the first threshold light value, the method can proceed to step 2212. Step 2210 can, in effect, allow controller 1408 to clear the injection sequence of anomalous interruptions in the light received by the detector, which may be caused by an air bubble inside cartridge 1302 blocking the light path between emitter 1414 and detector 1416, for example, provided that the amount of light subsequently Petition 870260002664, dated 12 / 01 / 2026, page 64 / 135 59 / 80 reaches or exceeds the first limit light value.
[0184] In step 2212, controller 1408 can determine if the motor current exceeds a first limit current value. The first limit current value can be determined and / or adjusted based on an indicative current from one end of the injection sequence. The first limit current value can be adjusted, for example, based on an indicative current from piston 1316 reaching the second end 1306 of cartridge 1302. If controller 1408 determines that the motor current does not exceed the first limit current value, controller 1408 can continue the injection sequence and method 2200 can revert to step 2208. If, on the other hand, controller 1408 determines that the motor current exceeds the first limit current value, method 2200 can proceed to step 2214 at which point controller 1408 can cause the injection sequence to terminate.
[0185] Method 2200 can, consequently, allow for the precise identification of the end of an injection sequence by identifying an instant when both the light received by detector 1416 and the motor current are indicative of the end of the dose. By performing steps 2208, 2210, and 2212 sequentially, false identifications of the end of the dose due to anomalous light interruptions or anomalous high-current events alone can be mitigated. Method 2200 can specifically reduce the impact of bubbles within the cartridge 1302 on the detection of the end of a drug dose.
[0186] FIG. 23 shows an exemplary method 2300 of operating the activation switch 1409 of the autoinjector 2 according to the disclosure. In particular, FIG. 23 represents an exemplary sequence of positions of the activation switch 1409 and corresponding functions of the autoinjector 2.
[0187] Initially, in step 2302, the autoinjector 2 can be arranged inside a package so that the plunger 1450 is in a pressed state and the autoinjector 2 is in a low-power sleep mode. In some embodiments, during manufacturing, the autoinjector 2 can be programmed into an awake or active state. In some embodiments, if the plunger 1450 is Petition 870260002664, dated 12 / 01 / 2026, p. 65 / 135 60 / 80 pressed for a predetermined period of time after programming, such as when the autoinjector is placed in the packaging, the autoinjector 2 can be configured to transition to low-power sleep mode. The predetermined time period can be any suitable time period, such as 60 minutes, 30 minutes, 15 minutes, 10 minutes, 5 minutes, 2 minutes, or any other suitable period. The autoinjector 2 can be sealed in the packaging so that the packaging indicates that the autoinjector 2 has not been used previously. The packaging can be made of any suitable material, including paper, cardboard, plastic, cellophane, and the like. The packaging can press against the plunger 1450 so that the plunger 1450 is flush or nearly flush with the housing 3 of the autoinjector 2 and the plunger 1450 is blocked from extending out of the autoinjector 2.With plunger 1450 in the pressed state, the circuit associated with activation switch 1409 may be open, thus keeping autoinjector 2 in low-power sleep mode.
[0188] In step 2304, the autoinjector 2 can be removed from the packaging so that the plunger 1450 is no longer pressed by the packaging and the plunger 1450 can extend out of the autoinjector 2. As the plunger 1450 transitions from the pressed state to the free or extended state, the plunger flange 1454 can contact or otherwise press the plunger switch 1448, thus completing the circuit associated with the activation switch 1409.
[0189] In step 2306, in response to the circuit associated with the activation switch 1409 being completed, the autoinjector can transition from low-power sleep mode to an active mode. In active mode, the autoinjector 2 can calibrate the touch sensor 1410. The autoinjector 2 can calibrate the touch sensor 1410 by detecting a value or measurement of the touch sensor 1410 in ambient air, i.e., not against a user's skin. The autoinjector 2 can perform such calibration during a predetermined period of time after the autoinjector 2 is removed from its packaging (in some cases immediately after removal) so that such calibration occurs before a user can expose their skin to the touch sensor 1410. In active mode, the autoinjector 2 can also detect whether the Petition 870260002664, dated 12 / 01 / 2026, page 66 / 135 61 / 80 emitter 1414 and / or detector 1416 are functioning correctly, detect if a needle is correctly positioned, detect if the translation mechanism motor 1366 is responsive and / or operational, and / or perform any other appropriate status tests. The autoinjector 2 can detect needle positioning, for example, using a switch or detector configured to report the needle position to the controller 1408. In active mode, the autoinjector 2 can also illuminate one or more backlights to allow a user to inspect a vial and / or a drug contained in the vial through the transparent window 50. In active mode, the autoinjector 2 can also display any other indication that the autoinjector 2 is ready for use.
[0190] In step 2308, the autoinjector 2 can be placed against a user's skin so that the plunger 1450 is pressed in the autoinjector 2. After the plunger 1450 is pressed, the circuit associated with the activation switch 1409 can transition to an open state. As described above with reference to FIG. 18 and method 2000, the autoinjector 2 can further detect skin contact using the touch sensor 1410. In response to the pressing of the plunger 1450 and detection of skin contact, the autoinjector 2 can initiate an injection sequence in step 2310. The injection sequence can be a sequence resulting in the injection of the user with a medication, as described earlier in this document.
[0191] In step 2312, the autoinjector 2 can be removed from the user's skin and the plunger 1450 can again extend out of the autoinjector 2. After the plunger 1450 extends out, the circuit associated with the activation switch 1409 can transition from the open state to the closed state. In response, the autoinjector 2 can terminate the injection sequence in step 2310 and, for example, initiate needle retraction from the patient by reversing the motor. The autoinjector 2 can initiate needle retraction if the injection sequence has proceeded to completion or if the autoinjector has been prematurely or accidentally removed from the skin to prevent wet injection. Alternatively, in some embodiments, the controller 1408 can determine whether a value received from the touch sensor 1410 is Petition 870260002664, dated 12 / 01 / 2026, page 67 / 135 62 / 80 indicates that autoinjector 2 remains in contact with the user's skin. If the value received by controller 1408 indicates that autoinjector 2 remains in contact with the user's skin, autoinjector 2 can pause the injection sequence, thus preventing wet injection. If plunger 1450 is pressed again, thus placing the circuit associated with activation switch 1409 in the open state, autoinjector 2 can resume the injection sequence.
[0192] According to the previous method 2300, the activation switch 1409 can serve to keep the autoinjector 2 in a low-power sleep mode when in the packaging, the autoinjector 2 transition to an active mode after removal from the packaging, indicate when the autoinjector 2 has been placed against a user's skin for an injection sequence, and indicate when the autoinjector 2 has been removed from the user's skin at the end of an injection sequence. Furthermore, a signal from the activation switch 1409 can be checked against a signal from the touch sensor 1410 to determine more accurately whether the autoinjector 2 has been removed from the user's skin or whether, for example, inadvertent or minor movement of the autoinjector has occurred. INJECTOR AND ASSEMBLY METHOD
[0193] As described above, the autoinjector 2 comprises several components and assemblies, as shown and described with reference to FIGS. 1-17A. As can be seen in FIGS. 24-30, the autoinjector 2 can be assembled by first assembling subassemblies, such as the first assembly 1492 and the second assembly 1490, and combining the assembled subassemblies.
[0194] In FIG. 24, an exploded view of the autoinjector is illustrated 2. The autoinjector 2 may include assemblies 1490 and 1492, each modular and configured to be assembled together, forming the autoinjector 2. In some examples, the autoinjector 2 may consist of a first assembly 1492 and a second assembly 1490. Each of the assemblies 1490 and 1492 comprises a plurality of components for assembling the autoinjector 2. The first assembly 1492 is configured to receive the second assembly 1490. Each assembly 1490, 1492 may include subassemblies 200, 1200, 1366, 1558 that make up the respective assemblies 1490, Petition 870260002664, dated 12 / 01 / 2026, p. 68 / 135 63 / 80 1492. For example, assembly 1492 includes fluid path assembly 200 and main body assembly 1200, and assembly 1490 includes ball screw assembly 1558 and translation mechanism 1366. A higher-level assembly 3000 can be applied to assemblies 1490 and 1492 once they are connected to each other.
[0195] The first assembly 1492 may include the needle mechanism 20, described above in detail with reference to FIGS. 5-11. The needle mechanism 20 includes the support 202 and may be configured to support and position the conduit 300, the actuator 320, the conveyor 340, the resilient member 370, the deployment mechanism 360 and the retraction mechanism 362 with the cover 380. The cover 380 and the conveyor 202 locate the conduit 300, conveyor 320, alternating valve 340, resilient member 370, deployment gear 360 and retraction gear 362 so that the needle mechanism 20 may operate when combined with other components of the autoinjector 2.
[0196] The first assembly 1492 may include a sterile connector assembly 250. The sterile connector assembly 250 may be connected to a part of the needle mechanism 20 and comprises elements configured to receive the cartridge 1302. As illustrated in FIGS. 24 and 25A, the sterile connector assembly may include the collar 1390, the retainer 1395, the polarizing member 1397, the actuator 1398, and the polarizing member 1497, which are described in more detail above with reference at least to FIGS. 13-14. Collar 1390 can be configured to receive conductor 1398 and polarizing member 1397. Retainer 1395 can be configured to engage with collar 1390. Retainer 1395 can have a plurality of fingers configured to fit into a plurality of grooves in collar 1390. Polarizing member 1497 can wrap around a portion of collar 1390 and assist in positioning retainer 1395.The retainer 1395 and the collar 1390 hold the actuator 1398 and the polarizing member 1397 together. The polarizing member 1397 pushes the retainer 1395 to apply a force to the actuator 1398, which, in turn, is pushed against the collar 1390. The sterile connector assembly 250 connects to the opening 206 of the holder 202, so that during operation of the... Petition 870260002664, dated 12 / 01 / 2026, page 69 / 135 64 / 80 autoinjector, fluid conduit 300 passes through sterile connector assembly 250 to cartridge 1302.
[0197] Together, the sterile connector assembly 250 and the needle mechanism 20 form the fluid path assembly 200 shown in FIGS. 25A-25C. The fluid circuit assembly 200 is configured to be connected to the main body assembly 1200, described further below.
[0198] Moving on to FIGS. 26A and 26B, the first assembly 1492 includes the main body assembly 1200. The main assembly 1200 can function as the base of the autoinjector 2. The main assembly 1200 includes the base 60, which can be configured to support the chassis 62 and the fluid path assembly 200. The base 60 can form a partial enclosure and can be configured to receive the chassis 62. The chassis 62 can be configured to support and position the fluid path assembly 200, as well as a portion of the housing 3 with a transparent part 500. The base 60 and the chassis 62 can position some or all of the activation switch components 1409 and related components, as described above with reference to FIGS. 3A-3C. In addition, base 60 and chassis 62 can support circuit board 1402, with the controller components, as well as a battery 1403.
[0199] The main body assembly 1200 and the fluid path assembly 200 can form the first assembly 1492, as shown in FIG. 27. In some examples, the shaft 1442 and the polarizing element 1444, as well as other elements of the activation switch 1409, can be connected to the base 60. The chassis 62 and the circuit board 1402 can also be added to the base 60. The fluid path assembly 200 can then be connected to the base 60 and the chassis 62. The housing 3 with the transparent part 500 can be added to the main body assembly 1200, forming a complete first assembly 1492.
[0200] FIGS. 28A and 28B illustrate the second set 1490 which corresponds to the translation mechanism 1366, described above with reference to at least FIGS. 4, 4B and 13-14. The translation mechanism 1366 may include a base end 1550. The base end 1550 may function as a base for Petition 870260002664, dated 12 / 01 / 2026, page 70 / 135 65 / 80 support an actuator (i.e., motor) 1552 and other elements of the translation assembly 1366.
[0201] The translation assembly 1366 includes the actuator 1552. The actuator 1552 can be connected to the translation mechanism 1366 and provide rotational motion to it. In some examples, the actuator 1552 may be a rotary actuator that is directly connected to the translation mechanism 1366. In other examples, the actuator 1552 may include a reduction gear set or a multiplier gear set, depending on the application. The actuator 1552 includes an output shaft configured to connect to an output gear 1554. The output gear 1554 can be rotated by the actuator 1552 and connected to the retainer 1566. The output gear 1554 and the retainer 1566 can be connected to the guide spindle assembly 1558.
[0202] The ball screw assembly 1558 can function to convert the rotational motion of the actuator 1552 into linear motion. As can be seen in FIG. 28A, the ball screw assembly 1558 can include a first screw 1367. As shown in more detail in FIGS. In 29A and 29B, a conduit 1372 may extend the length of the first screw 1367. The conduit 1372 may include an outer surface 1373 and an inner surface 1374, with a portion of the inner surface 1374 comprising a threaded region 1380. In some embodiments, the inner surface 1374 of the conduit 1372 may be completely covered by the threaded region 1380. The first screw 1367 receives the second screw 1369. The second screw 1369 includes a conduit that extends the entire length of the second screw 1369 and is threaded into the conduit surface. In addition, the second screw 1369 also has threads along its outer surface.The second screw 1369 is configured to receive a third screw 1371 which can connect with the piston 1316 and the second screw 1369. The threaded conduit of the first screw 1367 receives the external threads of the second screw 1369. The third screw 1371 is configured to be threaded into the internal thread of the second screw 1369. As the third screw 1371 is rotated by the actuator 1552, the first screw 1367 rotates. Petition 870260002664, dated 12 / 01 / 2026, page 71 / 135 66 / 80 together with the second screw 1369 to provide a linear translation that moves the piston 1316 into the cartridge 1302.
[0203] FIGS. 29A-29D illustrate an exemplary configuration of the first bolt 1367. The external bolt 1367 may generally comprise an upper portion 1378, a lower portion 1381 and a flange portion 1375. The flange portion 1375 may have a first surface 1376 and a second surface 1377 and separates the upper and lower portions 1378, 1381 of the external bolt 1367. A conduit 1372 extends the length of the external bolt 1367 and generally has a uniform diameter.
[0204] The upper portion 1378 may generally comprise one or more projections 1379 projecting from the first surface 1376 of the flange portion 1375. In some embodiments, one or more projections 1379 may be formed or partially formed by ejector pins during a molding process and are generally configured to fit into corresponding features of an output gear 1554 to assist in coupling the output gear 1554 and retainer 1566 to the first bolt 1367. It should be understood that there may be any number of one or more projections 1379 and that one or more projections 1379 may be of any suitable shape and / or size. In some embodiments, there are at least two projections, four projections, or five projections.
[0205] The lower portion 1381 may generally comprise a nozzle region 1382 and one or more protrusions 1383 extending radially outward from the outer surface 1373 of the conduit 1372 and longitudinally from the second surface 1377 of the flange portion 1375. Each of the one or more protrusions 1383 generally comprises a tip 1384 and a surrounding side edge 1385. One or more protrusions are configured to interlock with corresponding features found inside the piston 1316. The side edge 1385 has a chamfered design and the tip is generally tapered to facilitate the engagement of the external screw 1367 into the piston 1316 during the assembly process. The nozzle region 1382 extends from the tips 1384 of one or more protrusions 1383 Petition 870260002664, dated 12 / 01 / 2026, page 72 / 135 67 / 80 to the end of the lower portion 1381. The nose region 1382 may include a chamfer towards the end of the lower portion 1381 to further facilitate the fitting of the outer screw 1367 inside the piston 1316.
[0206] The configuration of the external screw 1367, including its dimensions and tolerances, can be selected to balance ease of assembly, strength and durability of the coupling mechanisms, and the degree of deformation of the piston 1540 when under external pressure. For example, the nozzle region 1382 can be configured to facilitate the insertion of the external screw 1367 into the piston 1316. Furthermore, the tips 1384 can be shaped and dimensioned to facilitate coupling with features of the piston 1316. By facilitating the insertion of the external screw 1367 into the piston 1316 during assembly, displacement of the piston 1316 from its position within the cartridge 1302 can be inhibited, and the integrity of the cartridge 1302 seal can be maintained during assembly.
[0207] The L1 length of the external screw 1367 can vary from about 12 mm to about 16 mm, including all subranges and values between them. In some embodiments, the L1 length of the external screw 1367 can vary from about 12.5 mm to about 15.5 mm; from about 12.75 mm to about 15.25 mm; from about 13 mm to about 15 mm; or from about 14 mm to about 15 mm. In certain embodiments, the length L1 of the external screw 1367 may be approximately 14.42 mm, approximately 14.48 mm, approximately 14.54 mm, approximately 14.60 mm, approximately 14.66 mm, approximately 14.72 mm, approximately 14.78 mm, approximately 14.84 mm, approximately 14.90 mm; or approximately 14.96 mm.
[0208] The length L2 of the lower portion 1381 of the external screw 1367 can vary from about 8.0 mm to about 13.0 mm, including all subranges and values between them. In some embodiments, the length L2 of the lower portion 1381 of the external screw 1367 can vary from about 8.0 mm to about 12.0 mm; from about 8.0 mm to about 11 mm; from about 8.0 mm to about 10.5 mm; from about 9.0 mm to about 12.0 mm; from about 9.0 mm to about 11.0 mm, from about 9.0 mm to about 10.5 mm; from about 9.5 mm to about 10.5 mm; or Petition 870260002664, dated 12 / 01 / 2026, page 73 / 135 68 / 80 from about 9.9 mm to about 10.2 mm. In certain embodiments, the length L2 of the lower portion 1381 of the external screw 1367 may be about 9.62 mm, about 9.68 mm, about 9.74 mm, about 9.80 mm, about 9.86 mm, about 9.92 mm, about 9.98 mm, about 10.04 mm, about 10.10 mm, about 10.16 mm, about 10.22 mm, about 10.28 mm, about 10.34 mm or about 10.40 mm.
[0209] The length L3 of the nozzle region 1382 of the lower portion 1381 of the external screw 1367 can vary from about 0.5 mm to about 7.0 mm, including all subranges and values between them. In some embodiments, the length L3 of the nozzle region 1382 of the lower portion 1381 of the external screw 1367 can vary from about 1.0 mm to about 4.5 mm; from about 1.5 mm to about 4.0 mm; from about 1.5 mm to about 3.5 mm; from about 2.0 mm to about 5.0 mm; from about 2.5 mm to about 5.0 mm; or from about 3.0 mm to about 5.0 mm. In certain embodiments, the length L3 of the nozzle region 1382 of the lower portion 1381 of the external screw 1367 may be approximately 5.41 mm, approximately 5.47 mm, approximately 5.53 mm, approximately 5.59 mm, approximately 5.65 mm, approximately 5.71 mm, approximately 5.77 mm, approximately 5.83 mm, approximately 5.89 mm, approximately 5.95 mm, approximately 6.01 mm, approximately 6.07 mm, approximately 6.13 mm, approximately 6.19 mm, approximately 6.25 mm, approximately 6.31 mm or approximately 6.37 mm.The tolerances for the lengths described in this document may be approximately 0.2 mm or less, approximately 0.15 mm or less, approximately 0.12 mm or less, approximately 0.10 mm or less, approximately 0.08 mm or less, or approximately 0.06 mm or less.
[0210] The threaded region 1380 of the conduit 1372 can generally be characterized by various diameter measurements. For example, the threaded region 1380 can be defined by a minor diameter measured between two opposite crests of the threading, a major diameter measured between two opposite bases of the threading, or a pitch diameter measured between the midpoints of the threading on both sides of the threaded region 1380. In some embodiments, the threaded region 1380 of the conduit 1372 may have a minor diameter ranging from about 6.75 mm to about 7.60 mm, a major diameter ranging from Petition 870260002664, dated 12 / 01 / 2026, page 74 / 135 69 / 80 approximately 7.75 mm to approximately 8.40 mm and / or a pitch diameter ranging from approximately 7.00 mm to 8.15 mm, including all sub-ranges and values in between.
[0211] The minor diameter may vary from about 6.75 mm to about 7.50 mm; from about 6.75 mm to about 7.40 mm; from about 6.75 mm to about 7.30 mm; from about 7.00 mm to about 7.50 mm; from about 7.00 mm to about 7.40 mm; from about 7.00 mm to about 7.30 mm; from about 7.15 mm to about 7.50 mm; from about 7.15 mm to about 7.40 mm; or from about 7.15 mm to about 7.30 mm. The major diameter may vary from about 7.75 mm to about 8.30 mm; from about 7.75 mm to about 8.20 mm; from about 7.75 mm to about 7.10 mm; from about 7.90 mm to about 8.30 mm; from about 7.90 mm to about 8.20 mm; from about 7.90 mm to about 8.10 mm; from about 8.05 mm to about 8.30 mm; from about 8.05 mm to about 8.25 mm; from about 8.05 mm to about 8.20 mm; from about 8.05 mm to about 8.15 mm; or from about 8.08 mm to about 8.15 mm.The pitch diameter can vary from about 7.00 mm to about 8.10 mm; from about 7.25 mm to about 8.00 mm; from about 7.25 mm to about 7.90 mm; from about 7.25 mm to about 7.75 mm; from about 7.25 mm to about 7.60 mm; from about 7.45 mm to about 8.10 mm; from about 7.45 mm to about 8.00 mm; from about 7.45 mm to about 7.90 mm; from about 7.45 mm to about 7.75 mm; from about 7.45 mm to about 7.60 mm; or from about 7.50 mm to about 7.60 mm.In certain embodiments, the smaller diameter may be approximately 6.93 mm, approximately 7.00 mm, approximately 7.07 mm, approximately 7.14 mm, approximately 7.21 mm, approximately 7.28 mm, approximately 7.35 mm, approximately 7.42 mm, or approximately 7.49 mm; The larger diameter can be approximately 7.78 mm, approximately 7.86 mm, approximately 7.94 mm, approximately 8.02 mm, approximately 8.10 mm, approximately 8.18 mm, approximately 8.26 mm, or approximately 8.34 mm, and the pitch diameter can be approximately 7.20 mm, approximately 7.26 mm, approximately 7.32 mm, approximately 7.38 mm, approximately 7.44 mm, approximately 7.50 mm, approximately 7.56 mm, approximately 7.62 mm, approximately 7.68 mm, approximately 7.74 mm, approximately 7.80 mm, or approximately 7.86 mm.
[0212] Together, the base end 1550 and the translation assembly 1366 can constitute the second assembly 1490. FIG. 28B illustrates a view in Petition 870260002664, dated 12 / 01 / 2026, page 75 / 135 70 / 80 perspective of the second set 1490. The second set 1490 is configured to be received by the first set 1492. When the second set 1490 is connected to the first set 1492, the actuator 1552 of the translation set 1366 connects to the circuit board 1402 of the first set 1492, so that the actuator 1552 is electrically connected to the circuit board 1402 and the controller components, as described above.
[0213] Returning to FIG. 4B, a perspective view of the first assembly 1492, the second assembly 1490, and cartridge 1302 is shown. The first assembly 1492 and the second assembly 1490 are configured to receive cartridge 1302, as described throughout this disclosure.
[0214] As can be seen in FIG. 30, the first assembly 1492 and the second assembly 1490 are connected. The transparent part 500 of the housing 3 has been removed to better visualize the connection of assemblies 1490 and 1492. In this example, the cartridge is loaded between assemblies 1490 and 1492. In some other examples, the cartridge may be absent from the autoinjector, as in a training device. Once the housing 3 with transparent parts is connected, the autoinjector 2 will be functional. The operation of the autoinjector 2 has been described above. The top-level assembly 3000 includes the assembled autoinjector 2 and labels 13 and 15, which are added to the front and back of the autoinjector 2, respectively, along with adhesive 12 and locking component 1610, as shown in FIG. 31.
[0215] FIG. 32 illustrates a flowchart for the assembly of autoinjector 2 and packaging of autoinjector 2. Box 5000 initiates the assembly method of autoinjector 2 with the assembly of the needle mechanism 20, connecting the conduit 300 to the support 202, along with the actuator 320, the conveyor 340, and the resilient member 370. The motor 320 and the conveyor 340 are operationally connected to the conduit 300. Box 5002 then shows that the fluid path assembly 200 is assembled, which means adding the sterile connector assembly 250 to the needle mechanism 20. The sterile connector assembly 250 is assembled by linearly stacking the polarizing member 1497, followed by the actuator. Petition 870260002664, dated 12 / 01 / 2026, page 76 / 135 71 / 80 1398, polarizing member 1397 and retainer 1395 around collar 1390. The retainer 1395 of the sterile connector assembly 250 is then connected to the opening 206 of the holder 202 of the needle mechanism 20, forming the fluid path assembly 200. Then, in the box 5004, the fluid path assembly 200 is connected with the main body assembly 1200 to form the first assembly 1492 (half A). The main assembly 1200 is assembled by connecting the chassis 62, the activation switch 1409, the circuit board 1402, and the battery 1403 to the base 60. The fluid path assembly 200 is then connected to the main body assembly 1200. The transparent portion 500 and the cover 3 are then connected to the main body assembly 1200 which contains the fluid path assembly 200. By connecting the cover 3 to the main body assembly 1200 and the fluid path assembly 200, the first portion 1492 is assembled.Moving on to the second assembly 1490, the translation mechanism 1366 is assembled by connecting the ball screw assembly 1558 to the actuator 1552. The ball screw assembly 1558 connects to an output of the actuator 1552. The actuator 1552 with the ball screw assembly 1558 makes up the translation assembly 1366, which is then connected to the base end 1550. After connecting the translation assembly 1366 to the base end 1550, the second assembly 1490 is assembled. In some examples, such as 5003, half B or the second assembly 1490 is assembled at the same time as half A or the first assembly 1492. In other examples, half B or the second assembly 1490 is assembled after half A or the first assembly 1492.The first assembly 1492 and the second assembly 1490 are then connected, including cartridge 1302, with cartridge 1302 connected to the fluid path assembly 200 and subsequently to the translation mechanism 1366, when the second assembly 1490 is connected to the first assembly 1492, as indicated in Box 5006. After the first assembly 1492 and the second assembly 1490 are connected with cartridge 1302 disposed within assemblies 1490 and 1492, the autoinjector device 2 is assembled. Box 5008 then adds adhesive 12 to the tissue contact surface 4. The locking pin 1610 is then added to the autoinjector 2, as are labels 13 and 15. Then, in the box. Petition 870260002664, dated 12 / 01 / 2026, page 77 / 135 72 / 80 5010, the autoinjector 2 receives the primary packaging, which includes a tray and a holder covered with a Tyvek lid with a label on the lid. Finally, box 5012 includes the final packaging with a tray, instructions for use (IFU), drug information, a packaging box with a label, and a tamper-evident seal. In some cases, the packaging box may be of the clamshell type. Although FIG. 32 illustrates one assembly method, any of the steps can be performed in another order that results in the complete assembly of the autoinjector 2 and its packaging.
[0216] During the assembly process of autoinjector 2, various quality checks can be performed to reduce defective parts and inoperative systems. For example, each part of the autoinjector can be photographed and checked by an assembler, by computer vision, or both, to detect any defects in the components of autoinjector 2. In some examples, the components of autoinjector 2 are photographed with an X-ray machine. In other examples, each of the components of autoinjector 2 is photographed multiple times at different stages of assembly and reviewed by an assembler, by computer vision, or both. In one example, the needle mechanism 20 can be viewed and analyzed with the components disassembled and then again after the needle mechanism is assembled. Furthermore, in another example, the needle mechanism 20 and the sterile connector system 250 can be viewed and analyzed after they are assembled.Similarly, in another example, the main body assembly 1200 can be photographed and analyzed, with particular interest in circuit board 1402 and related components. Autoinjector 2 can be repeatedly imaged and checked to ensure that the components are within specified tolerances.
[0217] A method for assembling the autoinjector 2, as shown in FIG. 32, may include other aspects and / or incorporate alternative aspects, as will be described in the following section. Although the assembly techniques described in this document may be considered as multiple distinct and independent methods, it should be understood that, in general, the techniques can be combined. Petition 870260002664, dated 12 / 01 / 2026, page 78 / 135 73 / 80 according to the present disclosure. In some respects, the assembly of autoinjector 2 can be segmented into five phases, in which certain tasks are performed with the aid of robotics and human intervention.
[0218] Phase 1 may generally comprise the formation of the patient needle mechanism 20, as described earlier in this document with reference to Box 5000 of FIG. 32. The initial step involves loading the individual components of the patient needle mechanism 20 onto a pallet in a sterile environment by means of a pallet loading process. After the pallet is fully loaded, it undergoes a digital imaging and object recognition process to verify the presence, positioning, and orientation of the components. After the verification process, a robotic system assembles the preloaded components. The fluid path or conduit 300 is connected to the conveyor 202, along with the actuator 320, the conveyor 340, the gears 360, 362, the spring or resilient member 370, and the cover 380. As illustrated in FIGS.33-34, the cover 380 is generally transparent or translucent to ensure an unobstructed line of sight for a camera used in the object recognition process. In some embodiments, a retainer or spring clip, shown among other components in FIG. 33 and individually in FIG. 35, may be introduced during the pallet loading process to assist in the installation of the spring 370 within the patient needle mechanism 20. The spring retainer may be removed during assembly once the spring 370 is secured in place by other components. After assembly of the patient needle mechanism 20 components, the needle 306 at the first end 302 of the conduit 300 undergoes another object recognition process to ensure that it is not damaged and / or is correctly positioned.
[0219] Phase 2 generally comprises the formation of the fluid path assembly 200, as described earlier in this document with reference to Box 5002 of FIG. 32. The components for assembling the sterile connector 250 are loaded onto the pallet and undergo an object recognition process to confirm the positioning and alignment of the components, which are then. Petition 870260002664, dated 12 / 01 / 2026, page 79 / 135 74 / 80 assembled by a robotic system. The robotic system linearly stacks the polarizing member 1497, the actuator 1398, the polarizing member 1397, and the retainer 1395 around the collar 1390. The sterile connector assembly 250 then undergoes a second object recognition process to verify component alignment. If the components are not correctly aligned, the robotic system may rotate one or more components until they fit together as expected. The fluid pathway assembly 200 is then formed by coupling the sterile connector assembly 250 to the patient needle mechanism 20, connecting the retainer 1395 of the sterile connector assembly 250 to the holder 202. The retainer 1395 can be inserted through the opening 206 of the holder 202. The sterile connector assembly 250 is generally coupled to the patient needle mechanism 20 by means of a locking mechanism. In one embodiment, the locking mechanism is a rotating latch.
[0220] Phase 3 generally comprises the formation of half A or the first assembly 1492, as described earlier in this document with reference to Box 5004 of FIG. 32. Initially, a cover 500 is loaded onto the pallet, followed by the formation of the printed circuit board (PCB) 1402. The formation of the PCB 102 generally includes a bending process of the flexible board terminals to shape and inspect the PCB 1402 terminals, ensuring proper alignment and connection. The bending radius is optimized to avoid cracking or damage to the terminals. After the formation of the PCB 1402, the components for assembling half A 1492, including the PCB 1402, are loaded onto the pallet and undergo an object recognition process to confirm the positioning and alignment of the components.A robotic system assembles the components by connecting the base 60 to the chassis 62, the activation switch 1409, the printed circuit board 1402, and the battery 1403 to form the main body assembly 1200. The fluid path assembly 200 is then coupled to the main body assembly 1200. The cover 500 is then coupled to the main body assembly 1200, which contains the fluid path assembly 200, to form the half assembly. Petition 870260002664, dated 12 / 01 / 2026, page 80 / 135 75 / 80 1492. Next, the firmware is loaded onto the PCBA board 1402. Throughout this phase, various components and processes are examined, including, but not limited to, evaluating the battery charge and power 1403, performing tests such as pressing the plunger 1450 to validate proper operation, confirming the sleep behavior of the autoinjector device 2, and ensuring that the autoinjector device 2 remains inactive until the designated activation timeout is reached.
[0221] Phase 4 generally comprises the formation of half B or second assembly 1490, as described earlier in this document with reference to Box 5003 of FIG. 32, and the joining of halves A and B 1490, 1492, as described earlier in this document with reference to Box 5006 of FIG. 32. The components for half B 1490 are loaded onto a pallet and undergo an object recognition process to confirm the positioning and alignment of the components, which are then assembled by a robotic system. The robotic system connects the ball screw assembly 1558 to the actuator output 1552 and to the gears 1554 and 1556 to form the translation mechanism 1366. The translation mechanism 1366 is then connected to the base end 1550 to form half B 1490. Halves A and B, 1490 and 1492, are then coupled together so that the drug cartridge 1302, loaded with the desired drug, is contained within the autoinjector device 2.The 1558 guide screw assembly can be adjusted by rotating the screws to different lengths to set the desired dose. In some embodiments, the autoinjector device 2 may have a separate mechanism for setting the desired dose or the ability to dispense variable dosage amounts. The completed autoinjector device 2 then undergoes functional testing, software finalization and verification, and a contact voltage check to ensure proper operation. In some embodiments, the contact voltage check involves applying a voltage to the electrical contacts of the autoinjector device 2 that is lower than the voltage required to drive the motor, but sufficient to ensure that the electrical connections of the autoinjector device 2 are functional. Then, the... Petition 870260002664, dated 12 / 01 / 2026, page 81 / 135 The 76 / 80 autoinjector device 2 is labeled, and the autoinjector device 2 undergoes an additional image verification process to inspect the labels.
[0222] Phase 5 generally comprises the application of the final labels, adhesives, and packaging, as described earlier in this document with reference to Boxes 5008, 5010, and 5012 of FIG. 32. Adhesive 12 and locking member 1612 are added to the tissue contact surface 3. The autoinjector device 2 is then loaded into the chosen packaging, which generally includes a tray and a holder, before being hermetically sealed with a lid. The sealed tray is then inspected, a label is added, and the tray is placed in the packaging box along with the instructions for use (IFU) and relevant information about the medicinal product. The packaging box is then sealed with a tamper-evident seal, and a packaging label is affixed.
[0223] It should be understood that the steps of one or more of the various methods described in this document may be combined in certain embodiments. Furthermore, in certain embodiments, fewer than all of the steps of a method described in this document may be performed and / or additional steps not described in this document may be performed. In addition, the steps described in this document do not necessarily need to be performed in the exact order presented.
[0224] Notably, reference in this document to a modality or a modality means that a particular feature, structure or characteristic described in connection with the modality may be included, employed and / or incorporated in one, some or all of the modalities of this disclosure. Uses or appearances of the phrase in a modality or in another modality in the descriptive report do not refer to the same modality, nor are they separate or alternative modalities necessarily mutually exclusive of one or more other modalities, nor are they limited to a single exclusive modality. The same applies to the terms implementation and example. This disclosure is not limited to any single aspect or its modality, nor any combinations and / or permutations of such aspects and / or modalities. Furthermore, Petition 870260002664, dated 12 / 01 / 2026, p. 82 / 135 77 / 80 Each aspect of this disclosure and / or any embodiment thereof may be used alone or in combination with one or more other aspects of this disclosure and / or any embodiment thereof. For the sake of brevity, certain permutations and combinations are not discussed and / or illustrated separately in this document.
[0225] Furthermore, as indicated above, an embodiment or implementation described in this document as exemplary should not be interpreted as preferred or advantageous, for example, in relation to other embodiments or implementations; rather, it is intended to convey or indicate that the embodiment or embodiments are exemplary embodiments.
[0226] This disclosure is further described by the following non-limiting items:
[0227] Item 1 is a method of assembling a medical device, the method comprising: forming a first assembly including: a main body; a needle mechanism; and a sterile connector operationally connected to a portion of the needle mechanism and configured to receive a cartridge; wherein the needle mechanism and the sterile connector form a fluid path assembly that couples to the main body; forming a second assembly including: a base end and a translation mechanism, wherein the translation mechanism is configured to engage the cartridge; combining the first assembly and the second assembly.
[0228] Item 2 is the method of item 1, further comprising loading the cartridge into the first set before combining the first set with the second set.
[0229] Item 3 is the method of item 2, in which the cartridge is filled with a medicine during loading in the first set.
[0230] Item 4 is the method of item 2, where the cartridge is filled with water or empty during loading in the first set.
[0231] Item 5 is the method of item 1, in which the main body includes a base, a chassis, a circuit board configured as a controller, and a switch. Petition 870260002664, dated 12 / 01 / 2026, page 83 / 135 78 / 80 mobile activation in relation to the base.
[0232] Item 6 is the method of item 1, wherein the needle mechanism includes a support, a shuttle movably coupled to the support, an actuator movably coupled to the support, a polarizing member configured to apply a polarizing force against the shuttle, and a fluid conduit coupled to the actuator.
[0233] Item 7 is the method of item 1, in which the translation mechanism includes: an actuator coupled to the end of the base; and a ball screw assembly.
[0234] Item 8 is the method of item 7, where the ball screw assembly includes a first screw, a second screw threaded into the first screw, and a third screw threaded into the second screw.
[0235] Item 9 is the method of item 8, further comprising: loading the cartridge into the first assembly before combining the first assembly with the second assembly; and wherein, when combining the first assembly and the second assembly, the first screw is set to engage the cartridge.
[0236] Item 10 is the method of item 1, further comprising: attaching, after combining the first set and the second set, an adhesive with a tissue contact surface to the medical device; and sealing, after combining the first set and the second set, the medical device in a package.
[0237] Item 11 is the method of item 10, where the packaging includes a seal configured to indicate evidence of tampering.
[0238] Item 12 is the method from item 1, where forming the first set includes: generating images of one or more components of the first set to identify defects.
[0239] Item 13 is the method of item O of claim 1, wherein the formation of the first assembly includes: bending a flexible portion of a printed circuit board assembly; and attaching the printed circuit board assembly to the main body.
[0240] Item 14 is a method for assembling a medical device, the method comprising: forming a first assembly including: a main body Petition 870260002664, dated 12 / 01 / 2026, page 84 / 135 79 / 80 having a base, a chassis, a circuit board configured as a controller and a movable activation switch relative to the base; a needle mechanism having a conveyor, a movably coupled alternating valve to the conveyor, a movably coupled actuator to the conveyor, a polarizer configured to apply a polarizing force against the alternating valve and a fluid conduit coupled to the actuator; a sterile connector operationally connected to a portion of the fluid conduit and configured to receive a cartridge; wherein the needle mechanism and the sterile connector form a fluid path assembly coupled to the base of the main body;forming a second assembly including: a base end, an actuator connected to the base end and a lead screw assembly having a first screw, a second screw threaded into the second screw, wherein the lead screw assembly is coupled to the actuator and forms a translation mechanism, the translation mechanism configured to engage the cartridge; combining the first assembly and the second assembly.
[0241] Item 15 is the method of item 14, further comprising: loading the cartridge into the first set before combining the first set with the second set.
[0242] Item 16 is the method of item 14, further comprising: attaching, after combining the first set and the second set, an adhesive plaster to the fabric attachment surface of the medical device; and sealing, after combining the first set and the second set, the medical device in a package.
[0243] Item 17 is the method of item 14, where forming the first set includes: generating images of one or more components of the first set to identify defects.
[0244] Item 18 is a method of assembling a first set of a medical device, the method comprising: forming a needle mechanism having a carrier, a switching valve movably coupled to the carrier, an actuator movably coupled to the carrier and a polarizing member in communication with the switching valve and the actuator; and Petition 870260002664, dated 12 / 01 / 2026, page 85 / 135 80 / 80 a fluid conduit coupled to the actuator; form a sterile connector configured to receive a cartridge; couple the needle mechanism to the sterile connector to form a fluid path assembly; couple the fluid path assembly to a base of the first assembly; and couple a printed circuit board assembly to the base of the first assembly.
[0245] Item 19 is the method of item 18, also comprising: generating images of one or more components of the first set to identify defects.
[0246] Item 20 is the method of item 18, further comprising: bending a flexible portion of a printed circuit board. Petition 870260002664, dated 12 / 01 / 2026, page 86 / 135
Claims
1 / 5 CLAIMS 1. A method of assembling a medical device, the method characterized in that it comprises: forming a first assembly including: a main body; a needle mechanism; and a sterile connector operationally connected to a portion of the needle mechanism and configured to receive a cartridge; wherein the needle mechanism and the sterile connector form a fluid path assembly that couples to the main body; forming a second assembly including: a base end and a translation mechanism, wherein the translation mechanism is configured to engage the cartridge; combining the first assembly and the second assembly.
2. Method according to claim 1, characterized in that it comprises: loading the cartridge into the first assembly before combining the first assembly with the second assembly.
3. Method according to claim 2, characterized in that the cartridge is filled with a medicine during loading in the first set.
4. Method according to claim 2, characterized in that the cartridge is filled with water or empty during loading in the first set.
5. Method according to claim 1, characterized in that the main body includes a base, a chassis, a circuit board configured as a controller, and a movable activation switch relative to the base.
6. Method according to claim 1, characterized in that the needle mechanism includes a conveyor, a shuttle movably coupled to the conveyor, an actuator movably coupled to the conveyor, a polarizing member configured to apply a polarizing force against the shuttle, and a fluid conduit coupled to the actuator.
7. Method according to claim 1, characterized in that the translation mechanism includes: an actuator coupled to the base end; and a lead screw assembly.
8. Method according to claim 7, characterized in that the lead screw assembly includes a first screw, a second screw threaded into the first screw, and a third screw threaded into the second screw.
9. A method according to claim 8, characterized in that it comprises: loading the cartridge into the first assembly before combining the first assembly with the second assembly; and in that, when combining the first assembly and the second assembly, the first screw is configured to engage the cartridge.
10. Method according to claim 1, characterized in that it comprises: coupling, after combining the first set and the second set, an adhesive plaster with a tissue coupling surface of the medical device; and sealing, after combining the first set and the second set, the medical device in a package.
11. Method according to claim 10, characterized in that the packaging includes a seal configured to indicate evidence of tampering.
12. Method, according to claim 1, characterized in that the formation of the first set includes: generating images of one or more components of the first set to identify defects.
13. Method, according to claim 1, characterized in that Petition 870250104624, dated 11 / 14 / 2025, p. 25 / 36 3 / 5, the formation of the first assembly includes: bending a flexible portion of a printed circuit board assembly; and attaching the printed circuit board assembly to the main body.
14. Method of assembling a medical device, the method characterized in that it comprises: forming a first assembly including: a main body having a base, a chassis, a circuit board configured as a controller and a movable activation switch relative to the base; a needle mechanism having a carrier, a shuttle movably coupled to the carrier, an actuator movably coupled to the carrier, a polarization configured to apply a polarization force against the shuttle and a fluid conduit coupled to the actuator; a sterile connector operationally connected to a portion of the fluid conduit and configured to receive a cartridge; wherein the needle mechanism and the sterile connector form a fluid path assembly coupled to the base of the main body;to form a second assembly including: a base end, an actuator connected to the base end and a lead screw assembly having a first screw, a second screw threaded into the first screw and a third screw threaded into the second screw; wherein the lead screw assembly is coupled to the actuator and forms a translation mechanism, the translation mechanism configured to engage the cartridge; combine the first assembly and the second assembly.
15. Method, according to claim 14, characterized in that it comprises: loading the cartridge into the first set before combining the first set with the second set.
16. Method according to claim 14, characterized in that it comprises: attaching, after combining the first set and the second set, an adhesive plaster to a tissue attachment surface of the medical device; and sealing, after combining the first set and the second set, the medical device in a package.
17. Method, according to claim 14, characterized in that the formation of the first set includes: generating images of one or more components of the first set to identify defects.
18. Method for assembling a first assembly of a medical device, the method characterized in that it comprises: forming a needle mechanism having a carrier, a shuttle movably coupled to the carrier, an actuator movably coupled to the carrier and a polarizing member communicating with the shuttle and the actuator; and a fluid conduit coupled to the actuator; forming a sterile connector configured to receive a cartridge; coupling the needle mechanism to the sterile connector to form a fluid path assembly; coupling the fluid path assembly to a base of the first assembly; and coupling a printed circuit board assembly to the base of the first assembly.
19. Method according to claim 18, characterized in that it comprises: generating images of one or more components of the first set to identify defects.
20. Method according to claim 18, characterized in that it comprises: Petition 870250104624, dated 11 / 14 / 2025, page 27 / 36 5 / 5 bending a flexible portion of a printed circuit board assembly. Petition 870250104624, dated 11 / 14 / 2025, page 28 / 36
